CA3086024A1 - Composition for suppressing fat accumulation - Google Patents
Composition for suppressing fat accumulationInfo
- Publication number
- CA3086024A1 CA3086024A1 CA3086024A CA3086024A CA3086024A1 CA 3086024 A1 CA3086024 A1 CA 3086024A1 CA 3086024 A CA3086024 A CA 3086024A CA 3086024 A CA3086024 A CA 3086024A CA 3086024 A1 CA3086024 A1 CA 3086024A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- lactic acid
- acid bacterium
- polysaccharide
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 109
- 238000009825 accumulation Methods 0.000 title claims abstract description 33
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 81
- 239000005017 polysaccharide Substances 0.000 claims abstract description 81
- 241000186605 Lactobacillus paracasei Species 0.000 claims abstract description 44
- 235000013305 food Nutrition 0.000 claims abstract description 36
- 208000008589 Obesity Diseases 0.000 claims abstract description 22
- 235000020824 obesity Nutrition 0.000 claims abstract description 22
- 208000004930 Fatty Liver Diseases 0.000 claims abstract description 17
- 206010019708 Hepatic steatosis Diseases 0.000 claims abstract description 17
- 208000010706 fatty liver disease Diseases 0.000 claims abstract description 17
- 231100000240 steatosis hepatitis Toxicity 0.000 claims abstract description 16
- 239000004480 active ingredient Substances 0.000 claims abstract description 15
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 218
- 239000004310 lactic acid Substances 0.000 claims description 110
- 241000894006 Bacteria Species 0.000 claims description 109
- 235000014655 lactic acid Nutrition 0.000 claims description 109
- 150000004804 polysaccharides Chemical class 0.000 claims description 80
- 239000000047 product Substances 0.000 claims description 60
- 210000005056 cell body Anatomy 0.000 claims description 29
- 230000007935 neutral effect Effects 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 235000001727 glucose Nutrition 0.000 claims description 13
- 229920001284 acidic polysaccharide Polymers 0.000 claims description 12
- 150000004805 acidic polysaccharides Chemical class 0.000 claims description 12
- 235000013361 beverage Nutrition 0.000 claims description 12
- 208000019423 liver disease Diseases 0.000 claims description 10
- 230000005976 liver dysfunction Effects 0.000 claims description 10
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical class CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 claims description 9
- 241000196324 Embryophyta Species 0.000 claims description 8
- 235000015203 fruit juice Nutrition 0.000 claims description 8
- 239000013589 supplement Substances 0.000 claims description 8
- 235000007119 Ananas comosus Nutrition 0.000 claims description 7
- 235000021107 fermented food Nutrition 0.000 claims description 6
- 235000013376 functional food Nutrition 0.000 claims description 6
- 150000002304 glucoses Chemical class 0.000 claims description 6
- 150000002704 mannoses Chemical class 0.000 claims description 6
- 244000099147 Ananas comosus Species 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 5
- 241000186660 Lactobacillus Species 0.000 abstract description 2
- 241001465754 Metazoa Species 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 206010019663 Hepatic failure Diseases 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 231100000835 liver failure Toxicity 0.000 abstract 1
- 208000007903 liver failure Diseases 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 43
- 239000003925 fat Substances 0.000 description 37
- 235000019197 fats Nutrition 0.000 description 37
- 241000699670 Mus sp. Species 0.000 description 33
- 238000000034 method Methods 0.000 description 29
- 235000013997 pineapple juice Nutrition 0.000 description 25
- 229920002444 Exopolysaccharide Polymers 0.000 description 24
- 235000009200 high fat diet Nutrition 0.000 description 23
- 230000037396 body weight Effects 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 20
- 239000002609 medium Substances 0.000 description 19
- 239000000523 sample Substances 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 16
- 230000009471 action Effects 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000002244 precipitate Substances 0.000 description 12
- 210000001596 intra-abdominal fat Anatomy 0.000 description 11
- 235000019786 weight gain Nutrition 0.000 description 11
- 150000001720 carbohydrates Chemical class 0.000 description 10
- 239000013641 positive control Substances 0.000 description 10
- 238000009395 breeding Methods 0.000 description 9
- 230000001488 breeding effect Effects 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000037406 food intake Effects 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 235000021314 Palmitic acid Nutrition 0.000 description 8
- 229960001031 glucose Drugs 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 8
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 7
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 7
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 7
- 239000005642 Oleic acid Substances 0.000 description 7
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 7
- 230000002378 acidificating effect Effects 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 7
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 241000234671 Ananas Species 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 210000003494 hepatocyte Anatomy 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000011369 resultant mixture Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000003579 anti-obesity Effects 0.000 description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 4
- 150000002772 monosaccharides Chemical class 0.000 description 4
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 238000012916 structural analysis Methods 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 102000016938 Catalase Human genes 0.000 description 3
- 108010053835 Catalase Proteins 0.000 description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 3
- 238000005349 anion exchange Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 235000015140 cultured milk Nutrition 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 2
- 240000006024 Lactobacillus plantarum Species 0.000 description 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 238000005571 anion exchange chromatography Methods 0.000 description 2
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000012470 diluted sample Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 229940072205 lactobacillus plantarum Drugs 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000006872 mrs medium Substances 0.000 description 2
- 239000003973 paint Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- OJDZKIIKLJJBRX-NANGHANQSA-N (2S,3R,4R,5S)-2,3,4,5-tetrahydroxyhexanal (2R,3S,4S,5R)-2,3,4,5-tetrahydroxyhexanal Chemical compound C[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O.C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O OJDZKIIKLJJBRX-NANGHANQSA-N 0.000 description 1
- CDVZCUKHEYPEQS-FALJYIPSSA-N (2S,3R,4S)-2,3,4,5-tetrahydroxypentanal (2R,3S,4R)-2,3,4,5-tetrahydroxypentanal Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)C=O.OC[C@@H](O)[C@H](O)[C@@H](O)C=O CDVZCUKHEYPEQS-FALJYIPSSA-N 0.000 description 1
- CDVZCUKHEYPEQS-KPXKHRLBSA-N (2s,3r,4r)-2,3,4,5-tetrahydroxypentanal;(2r,3s,4s)-2,3,4,5-tetrahydroxypentanal Chemical compound OC[C@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C=O CDVZCUKHEYPEQS-KPXKHRLBSA-N 0.000 description 1
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- VBUYCZFBVCCYFD-JJYYJPOSSA-N 2-dehydro-D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)C(O)=O VBUYCZFBVCCYFD-JJYYJPOSSA-N 0.000 description 1
- IZSRJDGCGRAUAR-MROZADKFSA-N 5-dehydro-D-gluconic acid Chemical compound OCC(=O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O IZSRJDGCGRAUAR-MROZADKFSA-N 0.000 description 1
- PENHKTNQUJMHIR-UHFFFAOYSA-N 5-methyl-3-phenyl-1,2-oxazole-4-carboxylic acid Chemical compound OC(=O)C1=C(C)ON=C1C1=CC=CC=C1 PENHKTNQUJMHIR-UHFFFAOYSA-N 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000272875 Ardeidae Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- RPUFVEIOVYTORQ-UOFHDTJTSA-N C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O.OC[C@H](O)[C@@H](O)[C@H](O)C(=O)CO Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O.OC[C@H](O)[C@@H](O)[C@H](O)C(=O)CO RPUFVEIOVYTORQ-UOFHDTJTSA-N 0.000 description 1
- 241000819038 Chichester Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N D-Arabitol Natural products OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- GUBGYTABKSRVRQ-UHFFFAOYSA-N D-Cellobiose Natural products OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- LKDRXBCSQODPBY-OEXCPVAWSA-N D-tagatose Chemical compound OCC1(O)OC[C@@H](O)[C@H](O)[C@@H]1O LKDRXBCSQODPBY-OEXCPVAWSA-N 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241001539176 Hime Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- HEBKCHPVOIAQTA-IMJSIDKUSA-N L-arabinitol Chemical compound OC[C@H](O)C(O)[C@@H](O)CO HEBKCHPVOIAQTA-IMJSIDKUSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 229910004619 Na2MoO4 Inorganic materials 0.000 description 1
- JQGGAELIYHNDQS-UHFFFAOYSA-N Nic 12 Natural products CC(C=CC(=O)C)c1ccc2C3C4OC4C5(O)CC=CC(=O)C5(C)C3CCc2c1 JQGGAELIYHNDQS-UHFFFAOYSA-N 0.000 description 1
- DKXNBNKWCZZMJT-UHFFFAOYSA-N O4-alpha-D-Mannopyranosyl-D-mannose Natural products O=CC(O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O DKXNBNKWCZZMJT-UHFFFAOYSA-N 0.000 description 1
- AYRXSINWFIIFAE-UHFFFAOYSA-N O6-alpha-D-Galactopyranosyl-D-galactose Natural products OCC1OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C1O AYRXSINWFIIFAE-UHFFFAOYSA-N 0.000 description 1
- 241000191996 Pediococcus pentosaceus Species 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 description 1
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 229940089837 amygdalin Drugs 0.000 description 1
- YZLOSXFCSIDECK-UHFFFAOYSA-N amygdalin Natural products OCC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC(C#N)c3ccccc3 YZLOSXFCSIDECK-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 239000002374 bone meal Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 108010079058 casein hydrolysate Proteins 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940093496 esculin Drugs 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 1
- YGHHWSRCTPQFFC-UHFFFAOYSA-N eucalyptosin A Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC(C#N)C=2C=CC=CC=2)OC(CO)C(O)C1O YGHHWSRCTPQFFC-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 229960002413 ferric citrate Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- DLRVVLDZNNYCBX-CQUJWQHSSA-N gentiobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-CQUJWQHSSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 235000015094 jam Nutrition 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
- DLRVVLDZNNYCBX-ABXHMFFYSA-N melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-ABXHMFFYSA-N 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- -1 patches Substances 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 1
- 229940120668 salicin Drugs 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 239000004460 silage Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011684 sodium molybdate Substances 0.000 description 1
- 235000015393 sodium molybdate Nutrition 0.000 description 1
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- WUUHFRRPHJEEKV-UHFFFAOYSA-N tripotassium borate Chemical compound [K+].[K+].[K+].[O-]B([O-])[O-] WUUHFRRPHJEEKV-UHFFFAOYSA-N 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Animal Husbandry (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Physiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
Abstract
This composition, which contains, as active ingredients, microbial cells of a lactobacilli belonging to Lactobacillus paracasei, a cultured product or fermented product thereof, or a polysaccharide produced by the same, is effective for inhibiting fat accumulation, and can be used as food, medication, and animal food for preventing or alleviating obesity, fatty liver, or hepatic failure.
Description
DESCRIPTION
Title of Invention:
COMPOSITION FOR SUPPRESSING FAT ACCUMULATION
Technical Field [0001]
The present invention relates to a composition for suppressing fat accumulation.
More specifically, the present invention relates to a composition for suppressing fat accumulation, comprising, as an active ingredient, a cell body of a lactic acid bacterium belonging to Lactobacillus paracasei, a cultured product or fermented product thereof, or a polysaccharide produced thereby.
Background Art
Title of Invention:
COMPOSITION FOR SUPPRESSING FAT ACCUMULATION
Technical Field [0001]
The present invention relates to a composition for suppressing fat accumulation.
More specifically, the present invention relates to a composition for suppressing fat accumulation, comprising, as an active ingredient, a cell body of a lactic acid bacterium belonging to Lactobacillus paracasei, a cultured product or fermented product thereof, or a polysaccharide produced thereby.
Background Art
[0002]
In recent years, the number of patients with a clinical condition called a metabolic syndrome, which shows symptoms such as fatty liver, diabetes, hypertension, and arteriosclerosis, has increased in Japan, Europe, and the United States.
Obesity is considered to be deeply involved in a metabolic syndrome. Obesity refers to a state in which the number of fat cells increases or fat is excessively accumulated in fat cells, by an excessive intake of energy due to overeating or a decrease in energy consumption due to insufficient exercise. It is therefore considered that obesity is prevented and improved by suppressing such fat accumulation.
In recent years, the number of patients with a clinical condition called a metabolic syndrome, which shows symptoms such as fatty liver, diabetes, hypertension, and arteriosclerosis, has increased in Japan, Europe, and the United States.
Obesity is considered to be deeply involved in a metabolic syndrome. Obesity refers to a state in which the number of fat cells increases or fat is excessively accumulated in fat cells, by an excessive intake of energy due to overeating or a decrease in energy consumption due to insufficient exercise. It is therefore considered that obesity is prevented and improved by suppressing such fat accumulation.
[0003]
In addition, fatty liver refers to a state in which neutral fats are excessively accumulated in liver or hepatocytes and is considered to be closely related to lifestyle-related diseases such as obesity, hyperlipidemia, and diabetes. It is considered as one of causes for accumulation of neutral fats in liver or hepatocytes that free fatty acids are taken up in liver or hepatocytes and accumulated therein as neutral fats.
In addition, fatty liver refers to a state in which neutral fats are excessively accumulated in liver or hepatocytes and is considered to be closely related to lifestyle-related diseases such as obesity, hyperlipidemia, and diabetes. It is considered as one of causes for accumulation of neutral fats in liver or hepatocytes that free fatty acids are taken up in liver or hepatocytes and accumulated therein as neutral fats.
[0004]
Various suggestions, such as ingestion of foods or supplements that promote the burning of body fat or suppress fat accumulation, and administration of an anti-obesity agent in the medical field, have been proposed to prevent and improve obesity. In addition, a method for suppressing fat accumulation in liver and the like have been proposed as a method for preventing and treating fatty liver. At present, however, from the viewpoint of safety and practicality, there are only a few that Date recu/Date received 2020-06-16 effectively prevent and improve obesity and fatty liver.
Various suggestions, such as ingestion of foods or supplements that promote the burning of body fat or suppress fat accumulation, and administration of an anti-obesity agent in the medical field, have been proposed to prevent and improve obesity. In addition, a method for suppressing fat accumulation in liver and the like have been proposed as a method for preventing and treating fatty liver. At present, however, from the viewpoint of safety and practicality, there are only a few that Date recu/Date received 2020-06-16 effectively prevent and improve obesity and fatty liver.
[0005]
On the other hand, lactic acid bacteria have been used for a long period of time when producing food products such as dairy products including fermented milk, lactic acid bacteria beverages, and fermented butter, and also utilized as materials for medicines, pharmaceuticals and the like because of their own effect on the regulation of intestine functions and their own various pharmacological actions. It has been reported as the action of lactic acid bacteria on fat accumulation that bacterial strains having a visceral fat-reducing effect were found among lactic acid bacteria of the genus Lactobacillus and Lactococcus (Patent Document 1); that lactic acid bacteria belonging to Lactobacillus gasseri have a fatty liver-inhibitory effect (Patent Document 2); and the like. In addition, as plant-derived lactic acid bacteria, Pediococcus pentosaceus strain LP28 and the like are known which have an effect of improving fatty liver and suppressing body fat accumulation (Non-Patent Document 3).
Prior Art Documents Patent Documents
On the other hand, lactic acid bacteria have been used for a long period of time when producing food products such as dairy products including fermented milk, lactic acid bacteria beverages, and fermented butter, and also utilized as materials for medicines, pharmaceuticals and the like because of their own effect on the regulation of intestine functions and their own various pharmacological actions. It has been reported as the action of lactic acid bacteria on fat accumulation that bacterial strains having a visceral fat-reducing effect were found among lactic acid bacteria of the genus Lactobacillus and Lactococcus (Patent Document 1); that lactic acid bacteria belonging to Lactobacillus gasseri have a fatty liver-inhibitory effect (Patent Document 2); and the like. In addition, as plant-derived lactic acid bacteria, Pediococcus pentosaceus strain LP28 and the like are known which have an effect of improving fatty liver and suppressing body fat accumulation (Non-Patent Document 3).
Prior Art Documents Patent Documents
[0006]
Patent Document 1: JP 2008-214253 A
Patent Document 2: JP 2008-24680 A
Non-Patent Documents
Patent Document 1: JP 2008-214253 A
Patent Document 2: JP 2008-24680 A
Non-Patent Documents
[0007]
Non-Patent Document 1: Appl. Microbiol. Biotechnol., 84, 341-347 (2009) Summary of Invention Problem to be solved by invention
Non-Patent Document 1: Appl. Microbiol. Biotechnol., 84, 341-347 (2009) Summary of Invention Problem to be solved by invention
[0008]
Under such background arts, it has been desired to develop a new composition for suppressing fat accumulation, containing a lactic acid bacterium as an active ingredient. The problem to be solved by the present invention is thus to provide a new composition for suppressing fat accumulation, comprising a lactic acid bacterium as an active ingredient, which is effective in preventing or improving obesity, fatty liver and liver dysfunction.
Means for solving the problem
Under such background arts, it has been desired to develop a new composition for suppressing fat accumulation, containing a lactic acid bacterium as an active ingredient. The problem to be solved by the present invention is thus to provide a new composition for suppressing fat accumulation, comprising a lactic acid bacterium as an active ingredient, which is effective in preventing or improving obesity, fatty liver and liver dysfunction.
Means for solving the problem
[0009]
Date recu/Date received 2020-06-16 The present inventor has made conducted intensive studies with the aim of developing a new composition for suppressing fat accumulation. As a result, the present inventor has found that polysaccharides produced by lactic acid bacteria belonging to Lactobacillus paracasei suppress hepatocytes from intaking free fatty acids to accumulate them as neutral fats; and that lactic acid bacteria belonging to Lactobacillus paracasei suppress body weight gain and visceral fat accumulation to have an anti-obesity action. On the basis of these findings, the present inventor has further studied and completed the present invention.
Date recu/Date received 2020-06-16 The present inventor has made conducted intensive studies with the aim of developing a new composition for suppressing fat accumulation. As a result, the present inventor has found that polysaccharides produced by lactic acid bacteria belonging to Lactobacillus paracasei suppress hepatocytes from intaking free fatty acids to accumulate them as neutral fats; and that lactic acid bacteria belonging to Lactobacillus paracasei suppress body weight gain and visceral fat accumulation to have an anti-obesity action. On the basis of these findings, the present inventor has further studied and completed the present invention.
[0010]
In one aspect of the present invention, the present invention relates to a composition for suppressing fat accumulation, comprising, as an active ingredient, a cell body of a lactic acid bacterium belonging to Lactobacillus paracasei, a cultured product or fermented product thereof, or a polysaccharide produced thereby.
The composition of the present invention can be preferably used to prevent or improve obesity and also prevent or improve fatty liver or liver dysfunction.
In the composition of the present invention, the lactic acid bacterium is preferably a lactic acid bacterium derived from a fig, and particularly preferably Lactobacillus paracasei strain IJH-SONE68 (Accession No. NITE BP-02242) or a lactic acid bacterium equivalent thereto.
In the composition of the present invention, a cultured product or fermented product of the lactic acid bacterium is preferably the one that can be obtained by cultivating or fermenting the lactic acid bacteria in the presence of a fruit juice of pineapple genus plant.
In the composition of the present invention, a polysaccharide produced by the lactic acid bacterium includes a neutral polysaccharide having a structure in which N-acetylglucosamines are linked with each other via a-1,6 bond, and an acidic polysaccharide composed mainly of glucoses and mannoses.
The composition of the present invention is preferably a food or drink composition, and the food or drink include a beverage, a functional food, a fermented food, and a supplement.
In addition, the composition of the present invention is preferably a pharmaceutical composition.
Furthermore, the composition of the present invention is preferably a feed composition.
Effect of Invention Date recu/Date received 2020-06-16
In one aspect of the present invention, the present invention relates to a composition for suppressing fat accumulation, comprising, as an active ingredient, a cell body of a lactic acid bacterium belonging to Lactobacillus paracasei, a cultured product or fermented product thereof, or a polysaccharide produced thereby.
The composition of the present invention can be preferably used to prevent or improve obesity and also prevent or improve fatty liver or liver dysfunction.
In the composition of the present invention, the lactic acid bacterium is preferably a lactic acid bacterium derived from a fig, and particularly preferably Lactobacillus paracasei strain IJH-SONE68 (Accession No. NITE BP-02242) or a lactic acid bacterium equivalent thereto.
In the composition of the present invention, a cultured product or fermented product of the lactic acid bacterium is preferably the one that can be obtained by cultivating or fermenting the lactic acid bacteria in the presence of a fruit juice of pineapple genus plant.
In the composition of the present invention, a polysaccharide produced by the lactic acid bacterium includes a neutral polysaccharide having a structure in which N-acetylglucosamines are linked with each other via a-1,6 bond, and an acidic polysaccharide composed mainly of glucoses and mannoses.
The composition of the present invention is preferably a food or drink composition, and the food or drink include a beverage, a functional food, a fermented food, and a supplement.
In addition, the composition of the present invention is preferably a pharmaceutical composition.
Furthermore, the composition of the present invention is preferably a feed composition.
Effect of Invention Date recu/Date received 2020-06-16
[0011]
The composition of the present invention is effective in suppressing fat accumulation and can be used to prevent or improve obesity and also prevent or improve fatty liver or liver dysfunction. The composition of the present invention can be used as a food or drink, a medicine, and a feed. The composition of the present invention comprises, as an active ingredient, a cell body of a lactic acid bacterium belonging to Lactobacillus paracasei, a cultured product or fermented product thereof, or a polysaccharide produced thereby. Therefore, the composition of the present invention has high safety, can be applied for a long period of time, can be supplied in a large amount at low cost, and has extremely high utility and practicality.
Brief Description of Drawings
The composition of the present invention is effective in suppressing fat accumulation and can be used to prevent or improve obesity and also prevent or improve fatty liver or liver dysfunction. The composition of the present invention can be used as a food or drink, a medicine, and a feed. The composition of the present invention comprises, as an active ingredient, a cell body of a lactic acid bacterium belonging to Lactobacillus paracasei, a cultured product or fermented product thereof, or a polysaccharide produced thereby. Therefore, the composition of the present invention has high safety, can be applied for a long period of time, can be supplied in a large amount at low cost, and has extremely high utility and practicality.
Brief Description of Drawings
[0012]
[Fig. 11 Fig. 1 shows microscope photographs of Lactobacillus paracasei strain IJH-SONE68. (A) in Fig. 1 is a gram-stained microscope photograph, and (B) in Fig.
1 is a scanning electron microscope (SEM) photograph.
[Fig. 21 Fig. 2 illustrates an isolation profile of anion exchange chromatography (TOYOPEARL DEAE-650M resin (Tosoh Corporation)) of exopolysaccharides from Lactobacillus paracasei strain IJH-SONE68. The exopolysaccharides were eluted with NaCl having a gradient concentration of 0 mM to 500 mM (broken line), and the exopolysaccharides in each fraction were monitored at 490 nm by a phenol sulfuric acid method (straight line).
[Fig. 31 Fig. 3 illustrates each NMR profile obtained by subjecting a neutral exopolysaccharide, which was obtained by purifying exopolysaccharides from Lactobacillus paracasei strain IJH-SONE68 with anion exchange column chromatography, to proton-NMR and carbon-NMR. (A) in Fig. 3 is the NMR profile of proton-NMR, and (B) in Fig. 3 is the NMR profile of carbon-NMR.
[Fig. 41 Fig. 4 illustrates results of structurally analyzing a neutral exopolysaccharide on the basis of the NMR profiles. These structural analysis results revealed that the neutral exopolysaccharide of Lactobacillus paracasei strain IJH-SONE68 has a structure in which N-acetylglucosamines are linked with each other via a-1,6 bond.
[Fig. 51 Fig. 5 is a graph illustrating that polysaccharides produced by Lactobacillus paracasei strain IJH-SONE68 has an action of suppressing fat accumulation in a concentration-dependent manner.
[Fig. 61 Fig. 6 is a graph illustrating changes in body weight gain of obesity model mice ingesting high fat diets, which ingested a fermented pineapple juice fermented with Date recu/Date received 2020-06-16 Lactobacillus paracasei strain UH-SONE68.
[Fig. 71 Fig. 7 is a graph illustrating that the body weight gain of obesity model mice ingesting high fat diets was suppressed by allowing the mice to ingest a fermented pineapple juice fermented with Lactobacillus paracasei strain UH-SONE68.
[Fig. 81 Fig. 8 is a graph illustrating that the visceral fat amount of obesity model mice ingesting high fat diets was suppressed by allowing the mice to ingest a fermented pineapple juice fermented with Lactobacillus paracasei strain UH-SONE68.
Embodiments for Carrying out Invention
[Fig. 11 Fig. 1 shows microscope photographs of Lactobacillus paracasei strain IJH-SONE68. (A) in Fig. 1 is a gram-stained microscope photograph, and (B) in Fig.
1 is a scanning electron microscope (SEM) photograph.
[Fig. 21 Fig. 2 illustrates an isolation profile of anion exchange chromatography (TOYOPEARL DEAE-650M resin (Tosoh Corporation)) of exopolysaccharides from Lactobacillus paracasei strain IJH-SONE68. The exopolysaccharides were eluted with NaCl having a gradient concentration of 0 mM to 500 mM (broken line), and the exopolysaccharides in each fraction were monitored at 490 nm by a phenol sulfuric acid method (straight line).
[Fig. 31 Fig. 3 illustrates each NMR profile obtained by subjecting a neutral exopolysaccharide, which was obtained by purifying exopolysaccharides from Lactobacillus paracasei strain IJH-SONE68 with anion exchange column chromatography, to proton-NMR and carbon-NMR. (A) in Fig. 3 is the NMR profile of proton-NMR, and (B) in Fig. 3 is the NMR profile of carbon-NMR.
[Fig. 41 Fig. 4 illustrates results of structurally analyzing a neutral exopolysaccharide on the basis of the NMR profiles. These structural analysis results revealed that the neutral exopolysaccharide of Lactobacillus paracasei strain IJH-SONE68 has a structure in which N-acetylglucosamines are linked with each other via a-1,6 bond.
[Fig. 51 Fig. 5 is a graph illustrating that polysaccharides produced by Lactobacillus paracasei strain IJH-SONE68 has an action of suppressing fat accumulation in a concentration-dependent manner.
[Fig. 61 Fig. 6 is a graph illustrating changes in body weight gain of obesity model mice ingesting high fat diets, which ingested a fermented pineapple juice fermented with Date recu/Date received 2020-06-16 Lactobacillus paracasei strain UH-SONE68.
[Fig. 71 Fig. 7 is a graph illustrating that the body weight gain of obesity model mice ingesting high fat diets was suppressed by allowing the mice to ingest a fermented pineapple juice fermented with Lactobacillus paracasei strain UH-SONE68.
[Fig. 81 Fig. 8 is a graph illustrating that the visceral fat amount of obesity model mice ingesting high fat diets was suppressed by allowing the mice to ingest a fermented pineapple juice fermented with Lactobacillus paracasei strain UH-SONE68.
Embodiments for Carrying out Invention
[0013]
The following detailed disclosures are made on the composition provided by the present invention for suppressing fat accumulation, comprising, as an active ingredient, a cell body of a lactic acid bacterium belonging to Lactobacillus paracasei, a cultured product or fermented product thereof, or a polysaccharide produced thereby.
1. The lactic acid bacterium in the present invention The lactic acid bacterium in the present invention is a lactic acid bacterium belonging to Lactobacillus paracasei and preferably a lactic acid bacterium derived from a fig. Specifically, the lactic acid bacterium includes Lactobacillus paracasei strain IJH-50NE68 that was isolated and identified from leaves of a fig according to the present invention. This strain was nationally deposited under the accession number of NITE P-02242 at Patent Microorganisms Depositary, National Institute of Technology and Evaluation (#122, 2-5-8 Kazusakamatari, Kisarazu-shi, Chiba 292-0818, Japan) on April 19, 2016. The deposition was then transferred to an international deposit under the Budapest Treaty and given the international deposit accession number of NITE
BP-02242 on May 26, 2017.
The following detailed disclosures are made on the composition provided by the present invention for suppressing fat accumulation, comprising, as an active ingredient, a cell body of a lactic acid bacterium belonging to Lactobacillus paracasei, a cultured product or fermented product thereof, or a polysaccharide produced thereby.
1. The lactic acid bacterium in the present invention The lactic acid bacterium in the present invention is a lactic acid bacterium belonging to Lactobacillus paracasei and preferably a lactic acid bacterium derived from a fig. Specifically, the lactic acid bacterium includes Lactobacillus paracasei strain IJH-50NE68 that was isolated and identified from leaves of a fig according to the present invention. This strain was nationally deposited under the accession number of NITE P-02242 at Patent Microorganisms Depositary, National Institute of Technology and Evaluation (#122, 2-5-8 Kazusakamatari, Kisarazu-shi, Chiba 292-0818, Japan) on April 19, 2016. The deposition was then transferred to an international deposit under the Budapest Treaty and given the international deposit accession number of NITE
BP-02242 on May 26, 2017.
[0014]
As illustrated in the photograph of Fig. 1, Lactobacillus paracasei strain IJH-50NE68 is a catalase-negative, gram-positive bacillus, and has mycological properties of forming a white colony and the mycological characteristic of conditional heterolactic fermentation. Furthermore, the strain has an ability to produce polysaccharides.
As illustrated in the photograph of Fig. 1, Lactobacillus paracasei strain IJH-50NE68 is a catalase-negative, gram-positive bacillus, and has mycological properties of forming a white colony and the mycological characteristic of conditional heterolactic fermentation. Furthermore, the strain has an ability to produce polysaccharides.
[0015]
A lactic acid bacteria equivalent to Lactobacillus paracasei strain IJH-50NE68 is also included in the present invention. Here, the equivalent lactic acid bacterium indicates a lactic acid bacterium that belongs to Lactobacillus paracasei and has an action of suppressing fat accumulation, like Lactobacillus paracasei strain Date recu/Date received 2020-06-16 IJH-SONE68. In addition, the equivalent lactic acid bacterium also indicates a lactic acid bacterium that produces polysaccharides having an action of suppressing fat accumulation, like polysaccharides produced by Lactobacillus paracasei strain IJH-SONE68. These equivalent lactic acid bacteria are obtained, for example, by performing usual mutation treatment technique, such as mutation and genetic recombination, on Lactobacillus paracasei strain IJH-SONE68 and, in addition, may be bacterial strains that have been bred by selecting natural mutation strains of Lactobacillus paracasei strain IJH-SONE68, and the like.
A lactic acid bacteria equivalent to Lactobacillus paracasei strain IJH-50NE68 is also included in the present invention. Here, the equivalent lactic acid bacterium indicates a lactic acid bacterium that belongs to Lactobacillus paracasei and has an action of suppressing fat accumulation, like Lactobacillus paracasei strain Date recu/Date received 2020-06-16 IJH-SONE68. In addition, the equivalent lactic acid bacterium also indicates a lactic acid bacterium that produces polysaccharides having an action of suppressing fat accumulation, like polysaccharides produced by Lactobacillus paracasei strain IJH-SONE68. These equivalent lactic acid bacteria are obtained, for example, by performing usual mutation treatment technique, such as mutation and genetic recombination, on Lactobacillus paracasei strain IJH-SONE68 and, in addition, may be bacterial strains that have been bred by selecting natural mutation strains of Lactobacillus paracasei strain IJH-SONE68, and the like.
[0016]
2. The active ingredient in the present invention The composition of the present invention contains, as an active ingredient, a cell body of the above-mentioned lactic acid bacterium, a cultured product or fermented product thereof, or a polysaccharide produced thereby.
The lactic acid bacterium can be cultured by a commonly used culture method such as liquid stationary culture, using a commonly used MRS medium or a modified medium thereof. The lactic acid bacterium can promote its growth by the culture in the presence of a fruit juice of a pineapple genus plant or its extract (WO
A). In addition, the lactic acid bacterium can also promote its growth by the culture in the presence of sake lees, sake lees extract or sake lees enzymes (JPH 03-172171 A, JPH 05-15366 A, and JP 2835548 B). As the lactic acid bacterium, a culture obtained after the cultivation may be used as it is, the obtained culture solution may be diluted or concentrated to be used, or the cell body recovered from the culture may be used. In addition, as long as the effect of the present invention is not impaired, various additional operations such as heat and freeze-dry may also be perfouned after the cultivation.
The lactic acid bacterium of the present invention may be viable or dead and may include both viable and dead, while polysaccharides are adhered to the cell surface of the lactic acid bacterium. The dead lactic acid bacterium may be crushed and preferably has polysaccharides adhered to the cell surface thereof. In addition, the fermented product of the lactic acid bacterium can be obtained by fermenting the lactic acid bacterium usually using glucose or the like as a nutrient source, and further using yeast extract, fruit juice of pineapple genus plants, sake lees, distilled spirit lees, etc., if necessary.
2. The active ingredient in the present invention The composition of the present invention contains, as an active ingredient, a cell body of the above-mentioned lactic acid bacterium, a cultured product or fermented product thereof, or a polysaccharide produced thereby.
The lactic acid bacterium can be cultured by a commonly used culture method such as liquid stationary culture, using a commonly used MRS medium or a modified medium thereof. The lactic acid bacterium can promote its growth by the culture in the presence of a fruit juice of a pineapple genus plant or its extract (WO
A). In addition, the lactic acid bacterium can also promote its growth by the culture in the presence of sake lees, sake lees extract or sake lees enzymes (JPH 03-172171 A, JPH 05-15366 A, and JP 2835548 B). As the lactic acid bacterium, a culture obtained after the cultivation may be used as it is, the obtained culture solution may be diluted or concentrated to be used, or the cell body recovered from the culture may be used. In addition, as long as the effect of the present invention is not impaired, various additional operations such as heat and freeze-dry may also be perfouned after the cultivation.
The lactic acid bacterium of the present invention may be viable or dead and may include both viable and dead, while polysaccharides are adhered to the cell surface of the lactic acid bacterium. The dead lactic acid bacterium may be crushed and preferably has polysaccharides adhered to the cell surface thereof. In addition, the fermented product of the lactic acid bacterium can be obtained by fermenting the lactic acid bacterium usually using glucose or the like as a nutrient source, and further using yeast extract, fruit juice of pineapple genus plants, sake lees, distilled spirit lees, etc., if necessary.
[0017]
Polysaccharides produced by the lactic acid bacterium can be obtained by isolating and purifying them from a culture of lactic acid bacteria belonging to Lactobacillus paracasei according to an ordinary method. Specifically, for example, Date recu/Date received 2020-06-16 the polysaccharides can be obtained by removing the cell body from a culture of lactic acid bacteria belonging to Lactobacillus paracasei by centrifugation, and precipitating polysaccharides from the obtained culture using ethanol, acetone, or the like.
In addition, the polysaccharides can be obtained by further isolating and purifying them by ion exchange chromatography.
Polysaccharides produced by the lactic acid bacterium can be obtained by isolating and purifying them from a culture of lactic acid bacteria belonging to Lactobacillus paracasei according to an ordinary method. Specifically, for example, Date recu/Date received 2020-06-16 the polysaccharides can be obtained by removing the cell body from a culture of lactic acid bacteria belonging to Lactobacillus paracasei by centrifugation, and precipitating polysaccharides from the obtained culture using ethanol, acetone, or the like.
In addition, the polysaccharides can be obtained by further isolating and purifying them by ion exchange chromatography.
[0018]
In the present invention, the polysaccharides produced by the lactic acid bacterium specifically include a neutral polysaccharide having a structure in which N-acetylglucosamines are linked with each other via a-1,6 bond, and an acidic polysaccharide composed mainly of glucoses and mannoses. This neutral polysaccharide can be obtained by isolating and purifying polysaccharides obtained from a culture of Lactobacillus paracasei strain IJH-SONE68 by anion exchange chromatography, as disclosed in Example 2 herein below. It was revealed from the proton-NMR and carbon-NMR profiles illustrated in Fig. 3 that this neutral polysaccharide has a structure in which N-acetylglucosamines are linked with each other by a-1,6 bonds. In addition, the Lactobacillus paracasei strain IJH-secretes an acidic polysaccharide mainly composed of glucose and mannose outside the cell body. More specifically, this acidic polysaccharide is composed of glucose, mannose, galactose, and rhamnose, and their composition ratio is approximately 10:170:
2:1.
In the present invention, the polysaccharides produced by the lactic acid bacterium specifically include a neutral polysaccharide having a structure in which N-acetylglucosamines are linked with each other via a-1,6 bond, and an acidic polysaccharide composed mainly of glucoses and mannoses. This neutral polysaccharide can be obtained by isolating and purifying polysaccharides obtained from a culture of Lactobacillus paracasei strain IJH-SONE68 by anion exchange chromatography, as disclosed in Example 2 herein below. It was revealed from the proton-NMR and carbon-NMR profiles illustrated in Fig. 3 that this neutral polysaccharide has a structure in which N-acetylglucosamines are linked with each other by a-1,6 bonds. In addition, the Lactobacillus paracasei strain IJH-secretes an acidic polysaccharide mainly composed of glucose and mannose outside the cell body. More specifically, this acidic polysaccharide is composed of glucose, mannose, galactose, and rhamnose, and their composition ratio is approximately 10:170:
2:1.
[0019]
3. The composition in the present invention The composition of the present invention can be used in various forms of a food or drink composition, a pharmaceutical composition, and a feed composition.
3. The composition in the present invention The composition of the present invention can be used in various forms of a food or drink composition, a pharmaceutical composition, and a feed composition.
[0020]
The food or drink of the food or drink composition are not particularly limited but include beverages such as soft drinks, carbonated drinks, nutritional drinks, fruit juice beverages, and lactic acid bacteria beverages, concentrated stock solutions of these beverages, powders for the preparation of these beverages, and the like; ice cream, sherbet and ice confectionery such as shaved ice; confectioneries such as candy, gummy, cereal, chewing gum, candy, gum, chocolate, tablet candy, snack, biscuit, jelly, jam, cream, and baked confectionery; dairy products such as processed milk, milk drink, fermented milk, drink yogurt, and butter; bread; enteral nutritious food, liquid food, childcare milk, sports drink; food such as puree; seat sake; and other functional foods.
In addition, the food or drink may be supplements, and the supplements may be in the form of, for example, granules, powders, or tablets.
Date recu/Date received 2020-06-16
The food or drink of the food or drink composition are not particularly limited but include beverages such as soft drinks, carbonated drinks, nutritional drinks, fruit juice beverages, and lactic acid bacteria beverages, concentrated stock solutions of these beverages, powders for the preparation of these beverages, and the like; ice cream, sherbet and ice confectionery such as shaved ice; confectioneries such as candy, gummy, cereal, chewing gum, candy, gum, chocolate, tablet candy, snack, biscuit, jelly, jam, cream, and baked confectionery; dairy products such as processed milk, milk drink, fermented milk, drink yogurt, and butter; bread; enteral nutritious food, liquid food, childcare milk, sports drink; food such as puree; seat sake; and other functional foods.
In addition, the food or drink may be supplements, and the supplements may be in the form of, for example, granules, powders, or tablets.
Date recu/Date received 2020-06-16
[0021]
The food or drink as disclosed above may be prepared by adding a cell body of a lactic acid bacterium belonging to Lactobacillus paracasei, a cultured product or fermented product thereof, or a polysaccharide produced thereby, to raw materials of food or drink, or prepared in the same manner as an usual food or drink. The addition of a cell body of a lactic acid bacterium belonging to Lactobacillus paracasei, a cultured product or fermented product thereof, or a polysaccharide produced thereby may be performed at any stage of the process of preparing the food or drink.
The food or drink may be prepared after a fermentation process of the added lactic acid bacteria.
Examples of such food or drink include fermented foods such as lactic acid bacterium beverages and fermented milks.
The food or drink as disclosed above may be prepared by adding a cell body of a lactic acid bacterium belonging to Lactobacillus paracasei, a cultured product or fermented product thereof, or a polysaccharide produced thereby, to raw materials of food or drink, or prepared in the same manner as an usual food or drink. The addition of a cell body of a lactic acid bacterium belonging to Lactobacillus paracasei, a cultured product or fermented product thereof, or a polysaccharide produced thereby may be performed at any stage of the process of preparing the food or drink.
The food or drink may be prepared after a fermentation process of the added lactic acid bacteria.
Examples of such food or drink include fermented foods such as lactic acid bacterium beverages and fermented milks.
[0022]
The content of a cell body of the lactic acid bacterium or a cultured product or fermented product thereof in the food or drink composition may be appropriately determined depending on the embodiment of the food or drink, but is the one so that a cell body of the lactic acid bacterium is usually contained in the food or drink composition preferably in the range of 1 x106 to lx 1012 cfu/g or lx 106 to lx 1012 cfu/ml, more preferably in the range of lx 107 to 1x1011 cfu/g or 1x107 to lx1011 cfu/ml. In the case where the lactic acid bacterium is a dead cell body, the cfu/g or cfu/ml can be replaced with the number of cells per g or the number of cells per ml. In the case of the polysaccharide produced by the lactic acid bacterium, the polysaccharide is usually contained in the food or drink composition at an amount of 0.001% or more by weight, preferably at an amount of 0.01% or more by weight, in terms of the weight of the polysaccharide.
The content of a cell body of the lactic acid bacterium or a cultured product or fermented product thereof in the food or drink composition may be appropriately determined depending on the embodiment of the food or drink, but is the one so that a cell body of the lactic acid bacterium is usually contained in the food or drink composition preferably in the range of 1 x106 to lx 1012 cfu/g or lx 106 to lx 1012 cfu/ml, more preferably in the range of lx 107 to 1x1011 cfu/g or 1x107 to lx1011 cfu/ml. In the case where the lactic acid bacterium is a dead cell body, the cfu/g or cfu/ml can be replaced with the number of cells per g or the number of cells per ml. In the case of the polysaccharide produced by the lactic acid bacterium, the polysaccharide is usually contained in the food or drink composition at an amount of 0.001% or more by weight, preferably at an amount of 0.01% or more by weight, in terms of the weight of the polysaccharide.
[0023]
The pharmaceutical composition is usually used by blending a cell body of the lactic acid bacterium, a cultured product or fermented product thereof or a polysaccharide produced thereby with a physiologically acceptable liquid or solid of a pharmaceutical carrier usually used, followed by the formulation. The dosage form of the pharmaceutical composition is not particularly limited, but includes tablets, pills, powders, solutions, suspensions, emulsions, granules, capsules, syrups, suppositories, injections, ointments, patches, eye drops, and nose drops.
The pharmaceutical composition is usually used by blending a cell body of the lactic acid bacterium, a cultured product or fermented product thereof or a polysaccharide produced thereby with a physiologically acceptable liquid or solid of a pharmaceutical carrier usually used, followed by the formulation. The dosage form of the pharmaceutical composition is not particularly limited, but includes tablets, pills, powders, solutions, suspensions, emulsions, granules, capsules, syrups, suppositories, injections, ointments, patches, eye drops, and nose drops.
[0024]
The content of a cell body of the lactic acid bacterium or a cultured product or fermented product thereof in the pharmaceutical composition may be appropriately determined depending on the dosage form, the dosage regimen, the age and sex of a Date recu/Date received 2020-06-16 subject, the kind of disease, the degree of disease, other conditions and the like, but is the one so that a cell body of the lactic acid bacterium is usually contained in the pharmaceutical composition preferably in the range of lx 106 to lx 1012 cfu/g or lx 106 to lx lU, =-,12 cfu/ml, more preferably in the range of lx107 to lx 10" cfu/g or lx 107 to lx 10"
cfu/ml. In the case where the lactic acid bacterium is a dead cell body, the cfu/g or cfu/ml can be replaced with the number of cells per g or the number of cells per ml. In the case of the polysaccharide produced by the lactic acid bacterium, the polysaccharide is usually contained in the pharmaceutical composition at an amount of 0.001%
or more by weight, preferably at an amount of 0.01% or more by weight, in terms of the weight of the polysaccharide.
The content of a cell body of the lactic acid bacterium or a cultured product or fermented product thereof in the pharmaceutical composition may be appropriately determined depending on the dosage form, the dosage regimen, the age and sex of a Date recu/Date received 2020-06-16 subject, the kind of disease, the degree of disease, other conditions and the like, but is the one so that a cell body of the lactic acid bacterium is usually contained in the pharmaceutical composition preferably in the range of lx 106 to lx 1012 cfu/g or lx 106 to lx lU, =-,12 cfu/ml, more preferably in the range of lx107 to lx 10" cfu/g or lx 107 to lx 10"
cfu/ml. In the case where the lactic acid bacterium is a dead cell body, the cfu/g or cfu/ml can be replaced with the number of cells per g or the number of cells per ml. In the case of the polysaccharide produced by the lactic acid bacterium, the polysaccharide is usually contained in the pharmaceutical composition at an amount of 0.001%
or more by weight, preferably at an amount of 0.01% or more by weight, in terms of the weight of the polysaccharide.
[0025]
The administration timing of the pharmaceutical composition of the present invention is not particularly limited but may be appropriately chosen depending on a subject to be applied. The pharmaceutical composition may also be administered prophylactically or used in a maintenance therapy. The administration mode may be preferably appropriately determined depending on the dosage form, age, sex and other conditions of the administered subject, the degree of symptoms of the administered subject, and the like. In any case, the pharmaceutical composition of the present invention may be administered once per day, administered dividedly into two or more times or administered once every several days or weeks.
The administration timing of the pharmaceutical composition of the present invention is not particularly limited but may be appropriately chosen depending on a subject to be applied. The pharmaceutical composition may also be administered prophylactically or used in a maintenance therapy. The administration mode may be preferably appropriately determined depending on the dosage form, age, sex and other conditions of the administered subject, the degree of symptoms of the administered subject, and the like. In any case, the pharmaceutical composition of the present invention may be administered once per day, administered dividedly into two or more times or administered once every several days or weeks.
[0026]
Examples of the feed of a feed composition include pet food, livestock feed and fish feed. Such a feed may be prepared by mixing common feed, for example, cereals, cakes, brans, fish meals, bone meals, oils and fats, skim milk powders, wheys, bitterns, mineral feeds, yeasts, or the like with a cell body of the lactic acid bacterium, a cultured product or fermented product thereof or a polysaccharide produced thereby.
In addition, for example, like the case of silage, a feed may be prepared through a fermentation process with the lactic acid bacterium added thereto. The prepared feed may be orally administered to general mammals, livestock, farmed fishes, pet animals or the like. In the case of farmed fishes, it may be adopted to spread fermented products, to which a cell body of the lactic acid bacterium, a cultured product or fermented product thereof or a polysaccharide produced thereby is added, to the farmed place of fishes.
Examples of the feed of a feed composition include pet food, livestock feed and fish feed. Such a feed may be prepared by mixing common feed, for example, cereals, cakes, brans, fish meals, bone meals, oils and fats, skim milk powders, wheys, bitterns, mineral feeds, yeasts, or the like with a cell body of the lactic acid bacterium, a cultured product or fermented product thereof or a polysaccharide produced thereby.
In addition, for example, like the case of silage, a feed may be prepared through a fermentation process with the lactic acid bacterium added thereto. The prepared feed may be orally administered to general mammals, livestock, farmed fishes, pet animals or the like. In the case of farmed fishes, it may be adopted to spread fermented products, to which a cell body of the lactic acid bacterium, a cultured product or fermented product thereof or a polysaccharide produced thereby is added, to the farmed place of fishes.
[0027]
The content of a cell body of the lactic acid bacterium or a cultured product or fermented product thereof in the feed composition may be appropriately determined Date recu/Date received 2020-06-16 depending on the embodiment of the feed or the administered subject, but is the one so that a cell body of the lactic acid bacterium is usually contained in the feed composition preferably in the range of 1x 106 to 1 x 1012 cfu/g or 1 x 106 to 1 x 1012 cfu/ml, more preferably in the range of lx 107 to lx 1011 cfu/g or lx 107 to lx 1011 cfu/ml. In the case where the lactic acid bacterium is a dead cell body, the cfu/g or cfu/ml can be replaced with the number of cells per g or the number of cells per ml. In the case of the polysaccharide produced by the lactic acid bacterium, the polysaccharide is usually contained in the feed composition at an amount of 0.001% or more by weight, preferably at an amount of 0.01% or more by weight, in terms of the weight of the polysaccharide.
The content of a cell body of the lactic acid bacterium or a cultured product or fermented product thereof in the feed composition may be appropriately determined Date recu/Date received 2020-06-16 depending on the embodiment of the feed or the administered subject, but is the one so that a cell body of the lactic acid bacterium is usually contained in the feed composition preferably in the range of 1x 106 to 1 x 1012 cfu/g or 1 x 106 to 1 x 1012 cfu/ml, more preferably in the range of lx 107 to lx 1011 cfu/g or lx 107 to lx 1011 cfu/ml. In the case where the lactic acid bacterium is a dead cell body, the cfu/g or cfu/ml can be replaced with the number of cells per g or the number of cells per ml. In the case of the polysaccharide produced by the lactic acid bacterium, the polysaccharide is usually contained in the feed composition at an amount of 0.001% or more by weight, preferably at an amount of 0.01% or more by weight, in terms of the weight of the polysaccharide.
[0028]
4. Use of the composition of the present invention A cell body of a lactic acid bacterium belonging to Lactobacillus paracasei, a cultured product or fermented product thereof, or a polysaccharide produced thereby has an action of suppressing hepatocytes from intaking free fatty acids to accumulate them as neutral fats, and suppresses body weight gain and visceral fat accumulation to have an anti-obesity action. Therefore, a composition containing, as an active ingredient, a cell body of a lactic acid bacterium belonging to Lactobacillus paracasei, a cultured product or fermented product thereof, or a polysaccharide produced thereby can be used to suppress fat accumulation and also suppress obesity. Specifically, the composition of the present invention can be used to prevent or improve obesity and also prevent or improve fatty liver or liver dysfunction. In addition, the composition of the present invention is effective in preventing or improving obesity and can be therefore utilized as materials of food or drink for maintaining and promoting health. In addition, the prevention or improvement of fatty liver or liver dysfunction leads to the maintenance, enhancement, recovery, and the like of physical strength, and the composition of the present invention can be therefore used as materials for food or drink for the maintenance, enhancement, and recovery of physical strength.
Examples
4. Use of the composition of the present invention A cell body of a lactic acid bacterium belonging to Lactobacillus paracasei, a cultured product or fermented product thereof, or a polysaccharide produced thereby has an action of suppressing hepatocytes from intaking free fatty acids to accumulate them as neutral fats, and suppresses body weight gain and visceral fat accumulation to have an anti-obesity action. Therefore, a composition containing, as an active ingredient, a cell body of a lactic acid bacterium belonging to Lactobacillus paracasei, a cultured product or fermented product thereof, or a polysaccharide produced thereby can be used to suppress fat accumulation and also suppress obesity. Specifically, the composition of the present invention can be used to prevent or improve obesity and also prevent or improve fatty liver or liver dysfunction. In addition, the composition of the present invention is effective in preventing or improving obesity and can be therefore utilized as materials of food or drink for maintaining and promoting health. In addition, the prevention or improvement of fatty liver or liver dysfunction leads to the maintenance, enhancement, recovery, and the like of physical strength, and the composition of the present invention can be therefore used as materials for food or drink for the maintenance, enhancement, and recovery of physical strength.
Examples
[0029]
Hereinafter, the present invention will be disclosed in more detail with reference to examples, but the present invention is not limited by these examples.
Hereinafter, the present invention will be disclosed in more detail with reference to examples, but the present invention is not limited by these examples.
[0030]
Example 1 Isolation and identification of lactic acid bacterium Date recu/Date received 2020-06-16 1. Isolation of lactic acid bacterium sample The leaves, stems, and fruits of a fig (variety "TOYOMITSU HIME") were chosen and cut into pieces of 2 to 3 mm using sterilized tweezers and scissors. Every five to six pieces were each then placed in a sterilized test tube containing MRS liquid medium, and statically cultured at 28 C and 37 C until the MRS medium as a standard medium for a lactic acid bacterium became turbid (proliferated). By the way, it took 2 to 4 days for the proliferation of the lactic acid bacterium candidate strains to be visible.
A part of each culture liquid of the lactic acid bacterium candidate strains was subjected to a line drawing paint on MRS agar medium using a disposable loop, followed by stationary culture. Among colonies formed on the agar medium, all of differently colored, lustrous and shaped colonies were picked up and subjected to a line drawing paint on a fresh MRS agar medium, and the colonies were purified.
H202 test was performed for each purified colony to verify the presence or absence of the production of a catalase enzyme. This is a test method for observing the presence or absence of oxygen generated when catalase is present, which is observed when microbial bodies are exposed to 10% H202 solution. By the way, a lactic acid bacterium produces no catalase.
As a result of attempting the search and isolation from a fig, one lactic acid bacterium candidate strain showing catalase-negative was obtained from the leaves of a fig as the isolation source.
Example 1 Isolation and identification of lactic acid bacterium Date recu/Date received 2020-06-16 1. Isolation of lactic acid bacterium sample The leaves, stems, and fruits of a fig (variety "TOYOMITSU HIME") were chosen and cut into pieces of 2 to 3 mm using sterilized tweezers and scissors. Every five to six pieces were each then placed in a sterilized test tube containing MRS liquid medium, and statically cultured at 28 C and 37 C until the MRS medium as a standard medium for a lactic acid bacterium became turbid (proliferated). By the way, it took 2 to 4 days for the proliferation of the lactic acid bacterium candidate strains to be visible.
A part of each culture liquid of the lactic acid bacterium candidate strains was subjected to a line drawing paint on MRS agar medium using a disposable loop, followed by stationary culture. Among colonies formed on the agar medium, all of differently colored, lustrous and shaped colonies were picked up and subjected to a line drawing paint on a fresh MRS agar medium, and the colonies were purified.
H202 test was performed for each purified colony to verify the presence or absence of the production of a catalase enzyme. This is a test method for observing the presence or absence of oxygen generated when catalase is present, which is observed when microbial bodies are exposed to 10% H202 solution. By the way, a lactic acid bacterium produces no catalase.
As a result of attempting the search and isolation from a fig, one lactic acid bacterium candidate strain showing catalase-negative was obtained from the leaves of a fig as the isolation source.
[0031]
2. Identification of the isolated strain The aforementioned lactic acid bacterium candidate strain was again cultured in MRS liquid medium, and the microbial bodies were obtained by centrifugation.
After the microbial bodies were treated with cell wall lytic enzyme, a genomic DNA
was extracted using DNAzol reagent.
According to the method as disclosed in Lane, DJ (1991), -165/235 rRNA
sequencing", Nucleic Acid Techniques in Bacterial Systematics, pp. 115-175, edited by E. Stackebrandt & M. Goodfellow. Chichester: Wiley, a genomic DNA PCR was performed using a genomic DNA as a template and using 27f primer and 1525r primer, thereby to amplify 16S rDNA part. Then, an objective fragment was recovered from agarose gel according to NucleoSpin Gel and PCR Clean-up kit (manufactured by Mahalay Nagel). A sequencing reaction by a dye terminator method for sequencing a base sequence was performed with Big Dye Terminator Cycle Sequencing FS Ready Reaction Kit ver. 3.1 (manufactured by ThermoFisher Scientific), and analysis was made with ABI PRISM 3130x1 Genetic Analyzer (manufactured by ThermoFisher Date recu/Date received 2020-06-16 Scientific). The base sequence of the analyzed 16S rDNA was subjected to a homology search by BLAST program and compared with the database of DNA data bank (DDBEEMBL/GenBank) to make a taxonomic identification on the isolated strain.
2. Identification of the isolated strain The aforementioned lactic acid bacterium candidate strain was again cultured in MRS liquid medium, and the microbial bodies were obtained by centrifugation.
After the microbial bodies were treated with cell wall lytic enzyme, a genomic DNA
was extracted using DNAzol reagent.
According to the method as disclosed in Lane, DJ (1991), -165/235 rRNA
sequencing", Nucleic Acid Techniques in Bacterial Systematics, pp. 115-175, edited by E. Stackebrandt & M. Goodfellow. Chichester: Wiley, a genomic DNA PCR was performed using a genomic DNA as a template and using 27f primer and 1525r primer, thereby to amplify 16S rDNA part. Then, an objective fragment was recovered from agarose gel according to NucleoSpin Gel and PCR Clean-up kit (manufactured by Mahalay Nagel). A sequencing reaction by a dye terminator method for sequencing a base sequence was performed with Big Dye Terminator Cycle Sequencing FS Ready Reaction Kit ver. 3.1 (manufactured by ThermoFisher Scientific), and analysis was made with ABI PRISM 3130x1 Genetic Analyzer (manufactured by ThermoFisher Date recu/Date received 2020-06-16 Scientific). The base sequence of the analyzed 16S rDNA was subjected to a homology search by BLAST program and compared with the database of DNA data bank (DDBEEMBL/GenBank) to make a taxonomic identification on the isolated strain.
[0032]
The lactic acid bacterium candidate strain isolated from leaves of a fig was named strain IJH-50NE68 and identified as Lactobacillus paracasei because it was 100% identical to a base sequence which was in the strain of Lactobacillus paracasei R094 already registered in DNA data bank (DDBEEMBL/GenBank) and which had NR-025880 as the accession number of the base sequence.
This strain was nationally deposited under the accession number of NITE
P-02242 at Patent Microorganisms Depositary, National Institute of Technology and Evaluation (#122, 2-5-8 Kazusakamatari, Kisarazu-shi, Chiba 292-0818, Japan) on April 19, 2016. The deposition was then transferred to an international deposit under the Budapest Treaty and given the international deposit accession number of NITE
BP-02242 on May 26, 2017.
The lactic acid bacterium candidate strain isolated from leaves of a fig was named strain IJH-50NE68 and identified as Lactobacillus paracasei because it was 100% identical to a base sequence which was in the strain of Lactobacillus paracasei R094 already registered in DNA data bank (DDBEEMBL/GenBank) and which had NR-025880 as the accession number of the base sequence.
This strain was nationally deposited under the accession number of NITE
P-02242 at Patent Microorganisms Depositary, National Institute of Technology and Evaluation (#122, 2-5-8 Kazusakamatari, Kisarazu-shi, Chiba 292-0818, Japan) on April 19, 2016. The deposition was then transferred to an international deposit under the Budapest Treaty and given the international deposit accession number of NITE
BP-02242 on May 26, 2017.
[0033]
3. Mycological properties of separated and identified lactic acid bacterium The aforementioned isolated and identified lactic acid bacterium strain IJH-50NE68 was a catalase-negative, gram-positive rod and had a white colony forming property, as shown in the photograph of Fig. 1, and further had the characteristic of conditional hetero-lactic acid fermentation and the ability of producing polysaccharides.
3. Mycological properties of separated and identified lactic acid bacterium The aforementioned isolated and identified lactic acid bacterium strain IJH-50NE68 was a catalase-negative, gram-positive rod and had a white colony forming property, as shown in the photograph of Fig. 1, and further had the characteristic of conditional hetero-lactic acid fermentation and the ability of producing polysaccharides.
[0034]
4. Saccharide assimilation ability of the isolated and identified lactic acid bacterium (1). Test method of assimilation ability The strain IJH-50NE68 was investigated for the assimilation ability of 49 kinds of saccharides according to the following test method.
The strain IJH-50NE68 was statically cultured in MRS liquid medium until the proliferation stationary phase. The microbial bodies obtained by centrifugation were washed with an appropriate amount of a suspension medium (manufactured by BioMeieux), and finally suspended in 2 mL of a suspension medium. A portion of the resultant suspension was added to 5 mL of a suspension medium to determine an amount (n) for McFarland turbidity to become 2. Subsequently, 2n of a microbial solution was added to API 50 CHL medium (manufactured by BioMerieux), and this solution was dispended to each well of API 50 CHL kit (manufactured by BioMerieux, Date recu/Date received 2020-06-16 49 kinds of saccharides were coated on the bottom of each well). Finally, mineral oil was overlaid and set in a tray containing a sterilized water. After culturing at 37 C for 48 hours, the presence or absence of the assimilation ability was assessed by observing the change in color tone in each well.
4. Saccharide assimilation ability of the isolated and identified lactic acid bacterium (1). Test method of assimilation ability The strain IJH-50NE68 was investigated for the assimilation ability of 49 kinds of saccharides according to the following test method.
The strain IJH-50NE68 was statically cultured in MRS liquid medium until the proliferation stationary phase. The microbial bodies obtained by centrifugation were washed with an appropriate amount of a suspension medium (manufactured by BioMeieux), and finally suspended in 2 mL of a suspension medium. A portion of the resultant suspension was added to 5 mL of a suspension medium to determine an amount (n) for McFarland turbidity to become 2. Subsequently, 2n of a microbial solution was added to API 50 CHL medium (manufactured by BioMerieux), and this solution was dispended to each well of API 50 CHL kit (manufactured by BioMerieux, Date recu/Date received 2020-06-16 49 kinds of saccharides were coated on the bottom of each well). Finally, mineral oil was overlaid and set in a tray containing a sterilized water. After culturing at 37 C for 48 hours, the presence or absence of the assimilation ability was assessed by observing the change in color tone in each well.
[0035]
5. Test results of the assimilation ability Table 1 shows the results of investigating the assimilation ability of the strain IJH-SONE68 against 49 kinds of saccharides.
5. Test results of the assimilation ability Table 1 shows the results of investigating the assimilation ability of the strain IJH-SONE68 against 49 kinds of saccharides.
[0036]
[Table 1]
Assimilation abilities of the strain UH-SONE68 against saccharides Substrates Assimilation abilities Control Glycerol Erythritol D-Arabinose L-Arabinose D-Ribose +
D-Xylose L-Xylose D-Adonitol Methyl-PD-xylopyranoside D-Galactose D-Glucose D-Fructose D-Mannose L-Sorbose L-Rhamnose Dulcitol Inositol D-Mannitol D-Sorbitol Methyl-aD-mannopyranoside Methyl-all-glucopyranoside N-Acetylglucosamine Date recu/Date received 2020-06-16 Amygdalin Arbutin Esculin + Ferric citrate Salicin D-Cellobiose D-Maltose D-Lactose D-Melibiose D-Sucrose D ¨ Trehalose Inulin D-Melezitose D-Raffinose Starch Glycogen Xylitol Gentibiose D-Turranose D-Lyxose D-Tagatose D-Fucose L-Fucose D-Arabitol L-Arabitol Gluconic acid 2-Ketogluconic acid 5-Ketogluconic acid In Table 1, + indicates the possession of assimilation ability, and ¨
indicates no possession of assimilation ability.
[Table 1]
Assimilation abilities of the strain UH-SONE68 against saccharides Substrates Assimilation abilities Control Glycerol Erythritol D-Arabinose L-Arabinose D-Ribose +
D-Xylose L-Xylose D-Adonitol Methyl-PD-xylopyranoside D-Galactose D-Glucose D-Fructose D-Mannose L-Sorbose L-Rhamnose Dulcitol Inositol D-Mannitol D-Sorbitol Methyl-aD-mannopyranoside Methyl-all-glucopyranoside N-Acetylglucosamine Date recu/Date received 2020-06-16 Amygdalin Arbutin Esculin + Ferric citrate Salicin D-Cellobiose D-Maltose D-Lactose D-Melibiose D-Sucrose D ¨ Trehalose Inulin D-Melezitose D-Raffinose Starch Glycogen Xylitol Gentibiose D-Turranose D-Lyxose D-Tagatose D-Fucose L-Fucose D-Arabitol L-Arabitol Gluconic acid 2-Ketogluconic acid 5-Ketogluconic acid In Table 1, + indicates the possession of assimilation ability, and ¨
indicates no possession of assimilation ability.
[0037]
Example 2 1. Isolation and purification of exopolysaccharides produced by the strain Exopolysaccharides produced by the strain IJH-SONE68 were isolated and purified according to the following method.
Date recu/Date received 2020-06-16 The strain IJH-SONE68 was statically cultured in MRS liquid medium until the proliferation stationary phase. 5 mL of the resultant culture solution was used as a seed culture solution, and inoculated on 5 L of a semisynthetic medium for producing exopolysaccharides (the composition thereof will be disclosed below), followed by static culture at 37 C for 120 hours. After the resultant culture solution was cooled to 4 C, proteins contained in the culture supernatant were denatured, and 202.5 mL of a 100% trichloroacetic acid aqueous solution was added thereto, mixed and allowed to stand for 30 minutes to remove them as precipitates in a later step. After the precipitates were removed by centrifugation, an equal amount of acetone was added to the collected supernatant and mixed, and the resultant mixture was allowed to stand at 4 C overnight to precipitate polysaccharides produced by the strain IJH-50NE68.
The precipitates were collected by centrifugation, and the resultant precipitates were then washed with 250 mL of 70% ethanol. After the precipitates were air-dried, 75 mL
of 50 mM Tris-HCl buffer (pH 8.0) was added to the resultant precipitates and mixed for 1 hour to dissolve the precipitates. After insoluble impurities were removed by centrifugation to recover a supernatant, 750 pL of 1 mg/mL DNase solution (Worthington, Inc.) and 750 pL of 1 mg/mL RNase solution (Nacalai Tesque, Inc.) were each added to the recovered supernatant, followed by being allowed to react at 37 C for 8 hours. Subsequently, 750 pL of 2 mg/mL proteinase K solution (manufactured by Wako Pure Chemical Industries, Ltd.) was added, and the resultant mixture was reacted at 37 C for 16 hours. The resultant solution after the reaction was cooled to 4 C, the added enzymes were each denatured, and 8.75 mL of a 100% trichloroacetic acid aqueous solution was then added thereto, mixed and allowed to stand for 1 hour to remove the enzymes as precipitates in the next centrifugation. The resultant precipitates were removed by centrifugation to obtain a supernatant, 262.5 mL
of 100%
ethanol was added to the obtained supernatant, the resultant mixture was thoroughly mixed, and the polysaccharides produced by the strain IJH-50NE68 strain were then recovered as precipitates by centrifugation. After the precipitates were washed with 50 mL of 70% ethanol, the precipitates were air-dried, an appropriate amount (about 25 mL) of a purified water was added thereto, and the resultant mixture was allowed to stand overnight at 4 C to dissolve the polysaccharides. For the polysaccharides sample after the dissolution, small molecules such as monosaccharides in the recovered sample were removed using an ultrafiltration unit (Merck Ltd.) of 10,000 MWCO
while replacing the solvent with a purified water, and a purified polysaccharide sample was thus obtained.
Example 2 1. Isolation and purification of exopolysaccharides produced by the strain Exopolysaccharides produced by the strain IJH-SONE68 were isolated and purified according to the following method.
Date recu/Date received 2020-06-16 The strain IJH-SONE68 was statically cultured in MRS liquid medium until the proliferation stationary phase. 5 mL of the resultant culture solution was used as a seed culture solution, and inoculated on 5 L of a semisynthetic medium for producing exopolysaccharides (the composition thereof will be disclosed below), followed by static culture at 37 C for 120 hours. After the resultant culture solution was cooled to 4 C, proteins contained in the culture supernatant were denatured, and 202.5 mL of a 100% trichloroacetic acid aqueous solution was added thereto, mixed and allowed to stand for 30 minutes to remove them as precipitates in a later step. After the precipitates were removed by centrifugation, an equal amount of acetone was added to the collected supernatant and mixed, and the resultant mixture was allowed to stand at 4 C overnight to precipitate polysaccharides produced by the strain IJH-50NE68.
The precipitates were collected by centrifugation, and the resultant precipitates were then washed with 250 mL of 70% ethanol. After the precipitates were air-dried, 75 mL
of 50 mM Tris-HCl buffer (pH 8.0) was added to the resultant precipitates and mixed for 1 hour to dissolve the precipitates. After insoluble impurities were removed by centrifugation to recover a supernatant, 750 pL of 1 mg/mL DNase solution (Worthington, Inc.) and 750 pL of 1 mg/mL RNase solution (Nacalai Tesque, Inc.) were each added to the recovered supernatant, followed by being allowed to react at 37 C for 8 hours. Subsequently, 750 pL of 2 mg/mL proteinase K solution (manufactured by Wako Pure Chemical Industries, Ltd.) was added, and the resultant mixture was reacted at 37 C for 16 hours. The resultant solution after the reaction was cooled to 4 C, the added enzymes were each denatured, and 8.75 mL of a 100% trichloroacetic acid aqueous solution was then added thereto, mixed and allowed to stand for 1 hour to remove the enzymes as precipitates in the next centrifugation. The resultant precipitates were removed by centrifugation to obtain a supernatant, 262.5 mL
of 100%
ethanol was added to the obtained supernatant, the resultant mixture was thoroughly mixed, and the polysaccharides produced by the strain IJH-50NE68 strain were then recovered as precipitates by centrifugation. After the precipitates were washed with 50 mL of 70% ethanol, the precipitates were air-dried, an appropriate amount (about 25 mL) of a purified water was added thereto, and the resultant mixture was allowed to stand overnight at 4 C to dissolve the polysaccharides. For the polysaccharides sample after the dissolution, small molecules such as monosaccharides in the recovered sample were removed using an ultrafiltration unit (Merck Ltd.) of 10,000 MWCO
while replacing the solvent with a purified water, and a purified polysaccharide sample was thus obtained.
[0038]
Date recu/Date received 2020-06-16 The purified polysaccharide sample was applied to an open column (2.5 x 22 cm) packed with TOYOPEARL DEAE-650M resin (Tosoh Corporation) previously equilibrated with 50 mM Tris-HC1 buffer (pH 8.0), and column work was performed to isolate and purify the sample to neutral polysaccharide fractions and acidic polysaccharide fractions. The same buffer was used as an elution solution, and a flow rate was fixed at 1 mL/min. In addition, eluates were collected in different test tubes at every 6 mL. First, from the beginning to 240 minutes, elution was made with the same buffer (Test Tube Nos. 1 to 40). Next, from 240 minutes to 600 minutes, a concentration gradient of 0 to 500 mM NaCl was prepared using the same buffer, and elution was continued with the gradient (Test Tube Nos. 41 to 100). The column isolation spectrum is illustrated in Fig. 2. After the presence of polysaccharides was confirmed by a phenol sulfuric acid method (disclosed below) for all the samples eluted in the test tubes, the confirmed solutions in the test tubes were collected as neutral polysaccharide fractions and acidic polysaccharide fraction, respectively. For each fraction, an ultrafiltration unit of 10,000 MWCO was used to remove small molecules such as monosaccharides in the recovered sample while replacing the solvent with purified water.
As a result, neutral polysaccharide fractions and acidic polysaccharide fractions were isolated and purified as exopolysaccharides produced by the strain IJH-SONE68.
Date recu/Date received 2020-06-16 The purified polysaccharide sample was applied to an open column (2.5 x 22 cm) packed with TOYOPEARL DEAE-650M resin (Tosoh Corporation) previously equilibrated with 50 mM Tris-HC1 buffer (pH 8.0), and column work was performed to isolate and purify the sample to neutral polysaccharide fractions and acidic polysaccharide fractions. The same buffer was used as an elution solution, and a flow rate was fixed at 1 mL/min. In addition, eluates were collected in different test tubes at every 6 mL. First, from the beginning to 240 minutes, elution was made with the same buffer (Test Tube Nos. 1 to 40). Next, from 240 minutes to 600 minutes, a concentration gradient of 0 to 500 mM NaCl was prepared using the same buffer, and elution was continued with the gradient (Test Tube Nos. 41 to 100). The column isolation spectrum is illustrated in Fig. 2. After the presence of polysaccharides was confirmed by a phenol sulfuric acid method (disclosed below) for all the samples eluted in the test tubes, the confirmed solutions in the test tubes were collected as neutral polysaccharide fractions and acidic polysaccharide fraction, respectively. For each fraction, an ultrafiltration unit of 10,000 MWCO was used to remove small molecules such as monosaccharides in the recovered sample while replacing the solvent with purified water.
As a result, neutral polysaccharide fractions and acidic polysaccharide fractions were isolated and purified as exopolysaccharides produced by the strain IJH-SONE68.
[0039]
A semisynthetic medium for producing polysaccharides was prepared by modifying a medium disclosed in Kimmel SA, Roberts RF., 'Development of a growth medium suitable for exopolysaccharide production by Lactobacillus delbrueckii ssp.
Bulgaricus RR.", Int. J. Food Microbiol., 40, 87-92 (1998), as follows:
A semisynthetic medium for producing polysaccharides was prepared by modifying a medium disclosed in Kimmel SA, Roberts RF., 'Development of a growth medium suitable for exopolysaccharide production by Lactobacillus delbrueckii ssp.
Bulgaricus RR.", Int. J. Food Microbiol., 40, 87-92 (1998), as follows:
[0040]
Semisynthetic medium for producing polysaccharides [g/L]
Glucose 20 Tween 80 1.0 Ammonium citrate 2.0 Sodium acetate 5.0 MgSat= 7H20 0.1 MnSat= 5H20 0.05 K2HPO4 2.0 Bacto casitone 10.0 Vitamin Soln. 2 mL
Trace element SoIn. 1 mL
Date recu/Date received 2020-06-16
Semisynthetic medium for producing polysaccharides [g/L]
Glucose 20 Tween 80 1.0 Ammonium citrate 2.0 Sodium acetate 5.0 MgSat= 7H20 0.1 MnSat= 5H20 0.05 K2HPO4 2.0 Bacto casitone 10.0 Vitamin Soln. 2 mL
Trace element SoIn. 1 mL
Date recu/Date received 2020-06-16
[0041]
Vitamin Soln. [g/L]
4-Aminobenzoic acid 0.05 Biotin 0.001 Folic acid 0.025 Lipoic acid 0.025 Nicotinic acid 0.1 Pantothenic acid 0.05 Pyridoxamin-HC1 0.25 Vitamin B12 0.05 Pyridoxine 0.025 Riboflavin 0.05 Thiamine 0.1
Vitamin Soln. [g/L]
4-Aminobenzoic acid 0.05 Biotin 0.001 Folic acid 0.025 Lipoic acid 0.025 Nicotinic acid 0.1 Pantothenic acid 0.05 Pyridoxamin-HC1 0.25 Vitamin B12 0.05 Pyridoxine 0.025 Riboflavin 0.05 Thiamine 0.1
[0042]
Trace element SoIn. is disclosed in Kets EPW, Galinski EA, de Bont JAM.
Carnitine: -A novel compatible solute in Lactobacillus plantarum", Arch.
Microbiol., 192, 243-248 (1994), and the composition is as follows:
Trace element SoIn. is disclosed in Kets EPW, Galinski EA, de Bont JAM.
Carnitine: -A novel compatible solute in Lactobacillus plantarum", Arch.
Microbiol., 192, 243-248 (1994), and the composition is as follows:
[0043]
Trace element SoIn. [g/L]
25% HC1 10 mL
FeC12= 4H20 1.5 CoC12= 6H20 0.19 MnC12= 4H20 0.1 ZnC12 0.07 H3B03 0.006 Na2MoO4= 2H20 0.036 NiC12= 6H20 0.024 CuC12. 2H20 0.002
Trace element SoIn. [g/L]
25% HC1 10 mL
FeC12= 4H20 1.5 CoC12= 6H20 0.19 MnC12= 4H20 0.1 ZnC12 0.07 H3B03 0.006 Na2MoO4= 2H20 0.036 NiC12= 6H20 0.024 CuC12. 2H20 0.002
[0044]
Phenol sulfuric acid method (DuBois M, Gilles KA, Hamilton JK, Rebers PA, Smith F., -Colorimetric method for determination of sugars and related substances", Anal. Chem., 28, 350-356 (1956))
Phenol sulfuric acid method (DuBois M, Gilles KA, Hamilton JK, Rebers PA, Smith F., -Colorimetric method for determination of sugars and related substances", Anal. Chem., 28, 350-356 (1956))
[0045]
30 pL of a subject sample was mixed with an equal amount of 5 w/v% phenol aqueous solution, and 150 pL of a concentrated sulfuric acid was added to the resultant mixture and mixed with each other to allow a reaction to start. Immediately after 10 Date recu/Date received 2020-06-16 minutes, the reaction solution was cooled by ice to stop the reaction. The concentration of saccharides was obtained by measuring the absorbance of the reaction solution at 490 nm. The concentration was determined using a calibration curve prepared by performing the same experiment using glucose as a standard.
30 pL of a subject sample was mixed with an equal amount of 5 w/v% phenol aqueous solution, and 150 pL of a concentrated sulfuric acid was added to the resultant mixture and mixed with each other to allow a reaction to start. Immediately after 10 Date recu/Date received 2020-06-16 minutes, the reaction solution was cooled by ice to stop the reaction. The concentration of saccharides was obtained by measuring the absorbance of the reaction solution at 490 nm. The concentration was determined using a calibration curve prepared by performing the same experiment using glucose as a standard.
[0046]
2. Structural analysis of neutral exopolysaccharide The neutral exopolysaccharide purified by the aforementioned anion exchange column chromatography (TOYOPEARL DEAE-650 M resin (Tosoh Corporation)) was subjected to proton-NMR and carbon-NMR, and the obtained NMR profiles are each illustrated in Fig. 3. The structural analysis results of the neutral exopolysaccharide from these NMR profiles are illustrated in Fig. 4.
From the structural analysis results, it was revealed that the neutral exopolysaccharide produced by the strain IJH-50NE68 has a structure in which N-acetylglucosamines are linked with each other via a-1,6 bond.
2. Structural analysis of neutral exopolysaccharide The neutral exopolysaccharide purified by the aforementioned anion exchange column chromatography (TOYOPEARL DEAE-650 M resin (Tosoh Corporation)) was subjected to proton-NMR and carbon-NMR, and the obtained NMR profiles are each illustrated in Fig. 3. The structural analysis results of the neutral exopolysaccharide from these NMR profiles are illustrated in Fig. 4.
From the structural analysis results, it was revealed that the neutral exopolysaccharide produced by the strain IJH-50NE68 has a structure in which N-acetylglucosamines are linked with each other via a-1,6 bond.
[0047]
3. Saccharide composition analysis of acidic exopolysaccharide The saccharide composition analysis of the aforementioned acidic exopolysaccharide purified by the anion exchange column chromatography was performed by measuring the composition by a high performance liquid chromatography (HPLC) method.
A 7-fold diluted sample solution was prepared by mixing 10 pi, of the purified acidic exopolysaccharide (7.3 mg/mL) and 60 pL of water and placed in a test tube.
20 pt of the diluted sample solution was collected from the test tube, dried under reduced pressure, and 100 pL of 2 mol/L trifluoroacetic acid was added thereto to dissolve the dried sample. The resultant solution was substituted with nitrogen, sealed under a reduced pressure, hydrolyzed at 100 C for 6 hours, and then dried under a reduced pressure. To the obtained residue, 200 pt of water was added, dissolved, and filtrated with 0.22 pin filter, to obtain a sample solution for measurement.
The sample solution for measurement was 10-fold diluted with water to obtain a sample solution for dilution measurement. 50 pt of each of these sample solutions was analyzed.
HPLC
system: LC-20A system (Shimadzu Corporation) and spectrofluorophotometer M-10AxL (Shimadzu Corporation) were used as analytical instruments. The analysis conditions were as follows:
Column: TSK-gel Sugar AXG 4.6 mml. D.>< 15 cm (Tosoh Corporation) Column temperature: 70 C
Mobile phase: 0.5 mol/L potassium borate buffer, pH 8.7 Date recu/Date received 2020-06-16 Mobile phase flow rate: 0.4 mL/min Post column labeling: reaction reagent: 1 w/v% arginine = 3 w/v% boric acid Reaction reagent flow rate: 0.5 mL/min Reaction temperature: 150 C
Detection wavelength: Ex. 320 nm, Em. 430 nm
3. Saccharide composition analysis of acidic exopolysaccharide The saccharide composition analysis of the aforementioned acidic exopolysaccharide purified by the anion exchange column chromatography was performed by measuring the composition by a high performance liquid chromatography (HPLC) method.
A 7-fold diluted sample solution was prepared by mixing 10 pi, of the purified acidic exopolysaccharide (7.3 mg/mL) and 60 pL of water and placed in a test tube.
20 pt of the diluted sample solution was collected from the test tube, dried under reduced pressure, and 100 pL of 2 mol/L trifluoroacetic acid was added thereto to dissolve the dried sample. The resultant solution was substituted with nitrogen, sealed under a reduced pressure, hydrolyzed at 100 C for 6 hours, and then dried under a reduced pressure. To the obtained residue, 200 pt of water was added, dissolved, and filtrated with 0.22 pin filter, to obtain a sample solution for measurement.
The sample solution for measurement was 10-fold diluted with water to obtain a sample solution for dilution measurement. 50 pt of each of these sample solutions was analyzed.
HPLC
system: LC-20A system (Shimadzu Corporation) and spectrofluorophotometer M-10AxL (Shimadzu Corporation) were used as analytical instruments. The analysis conditions were as follows:
Column: TSK-gel Sugar AXG 4.6 mml. D.>< 15 cm (Tosoh Corporation) Column temperature: 70 C
Mobile phase: 0.5 mol/L potassium borate buffer, pH 8.7 Date recu/Date received 2020-06-16 Mobile phase flow rate: 0.4 mL/min Post column labeling: reaction reagent: 1 w/v% arginine = 3 w/v% boric acid Reaction reagent flow rate: 0.5 mL/min Reaction temperature: 150 C
Detection wavelength: Ex. 320 nm, Em. 430 nm
[0048]
Chromatograms of samples prepared from the acidic exopolysaccharide and calibration curve data of each monosaccharide were obtained. The concentrations of constituent saccharides of the acidic exopolysaccharide in the samples were determined from calibration curves. The obtained results are shown in Table 2.
Chromatograms of samples prepared from the acidic exopolysaccharide and calibration curve data of each monosaccharide were obtained. The concentrations of constituent saccharides of the acidic exopolysaccharide in the samples were determined from calibration curves. The obtained results are shown in Table 2.
[0049]
[Table 2]
Constituent saccharides of acidic exopolysaccharide Acidic exopolysaccharide Concentration in sample (mg/mL) Rhamnose 0.0204 Ribose n.d.
Mannose 3.43 Monosaccharides Arabinose n.d.
Galactose 0.0384 Xylose n.d.
Glucose 0.219 In the Table, n.d. indicates no detection.
[Table 2]
Constituent saccharides of acidic exopolysaccharide Acidic exopolysaccharide Concentration in sample (mg/mL) Rhamnose 0.0204 Ribose n.d.
Mannose 3.43 Monosaccharides Arabinose n.d.
Galactose 0.0384 Xylose n.d.
Glucose 0.219 In the Table, n.d. indicates no detection.
[0050]
Example 3 Fat accumulation-suppressing action of polysaccharides produced by the strain The fat accumulation-suppressing action of the polysaccharide sample containing the neutral polysaccharide fractions and the acidic polysaccharide fractions, which were exopolysaccharides produced by the strain IJH-SONE68 and obtained in Example 2, was investigated according to the method disclosed below.
Example 3 Fat accumulation-suppressing action of polysaccharides produced by the strain The fat accumulation-suppressing action of the polysaccharide sample containing the neutral polysaccharide fractions and the acidic polysaccharide fractions, which were exopolysaccharides produced by the strain IJH-SONE68 and obtained in Example 2, was investigated according to the method disclosed below.
[0051]
1. Test method Human liver cancer-derived cell line, HuH-7 cells, were used as test subjects.
HuH-7 cells were cultured in DMEM medium (Dulbecco's modified Eagle medium (containing high glucose, L-glutamine, phenol red, and sodium pyruvate)) containing 10 v/v% FBS (fetal bovine serum), 100 U/mL penicillin G, and 100 pg/mL
streptomycin.
Date recu/Date received 2020-06-16 The resultant confluent cells were suspended in a new DMEM medium and seeded on a 24-well cell culture plate at 8 x 104 cells/well. The liquid volume per well at that time was 500 pt. After culturing for 24 hours, a solution of palmitic acid (PA) and oleic acid (OA) (PA/OA solution) (= 1:2, dissolved in DMSO)) was added to each well at a final concentration of 600 pM (PA: 200 pM and OA: 400 pM)), and further cultured for 24 hours to start intake of fatty acids. At that time, each polysaccharide sample (final concentration: 4-400 pg/mL) was added at the same time, and the suppression on the intake of fatty acids into cells was evaluated.
1. Test method Human liver cancer-derived cell line, HuH-7 cells, were used as test subjects.
HuH-7 cells were cultured in DMEM medium (Dulbecco's modified Eagle medium (containing high glucose, L-glutamine, phenol red, and sodium pyruvate)) containing 10 v/v% FBS (fetal bovine serum), 100 U/mL penicillin G, and 100 pg/mL
streptomycin.
Date recu/Date received 2020-06-16 The resultant confluent cells were suspended in a new DMEM medium and seeded on a 24-well cell culture plate at 8 x 104 cells/well. The liquid volume per well at that time was 500 pt. After culturing for 24 hours, a solution of palmitic acid (PA) and oleic acid (OA) (PA/OA solution) (= 1:2, dissolved in DMSO)) was added to each well at a final concentration of 600 pM (PA: 200 pM and OA: 400 pM)), and further cultured for 24 hours to start intake of fatty acids. At that time, each polysaccharide sample (final concentration: 4-400 pg/mL) was added at the same time, and the suppression on the intake of fatty acids into cells was evaluated.
[0052]
After 24 hours, the culture solution in each well was removed with an aspirator, and 500 pt of PBS (phosphate buffered saline) was added thereto to wash the cells and the wells. After removing the PBS, 250 pL of 10 w/v% formalin solution was added, and the cells were immobilized for 10 minutes. Subsequently, the wells were washed twice with 500 pL of PBS, and after removing the PBS, 150 pL of a color former solution (triglyceride E-Test Wako) was added, and a color reaction was performed at 37 C for 30 minutes. After the reaction, 100 pt of the reaction solution was recovered from each well, and the absorbance at 600 nm was measured to determine and compare the amount of fatty acid incorporated into the cells as the amount of intracellular triglyceride (neutral fat). A polysaccharide produced by Lactobacillus plantarum strain 5N35N (Accession No. NITE P-6) was used as a control.
After 24 hours, the culture solution in each well was removed with an aspirator, and 500 pt of PBS (phosphate buffered saline) was added thereto to wash the cells and the wells. After removing the PBS, 250 pL of 10 w/v% formalin solution was added, and the cells were immobilized for 10 minutes. Subsequently, the wells were washed twice with 500 pL of PBS, and after removing the PBS, 150 pL of a color former solution (triglyceride E-Test Wako) was added, and a color reaction was performed at 37 C for 30 minutes. After the reaction, 100 pt of the reaction solution was recovered from each well, and the absorbance at 600 nm was measured to determine and compare the amount of fatty acid incorporated into the cells as the amount of intracellular triglyceride (neutral fat). A polysaccharide produced by Lactobacillus plantarum strain 5N35N (Accession No. NITE P-6) was used as a control.
[0053]
2. Test results The evaluation of fatty acid intake was performed twice (1st and 2nd), and the obtained results are shown in Table 3.
2. Test results The evaluation of fatty acid intake was performed twice (1st and 2nd), and the obtained results are shown in Table 3.
[0054]
[Table 3]
Accumulation amount of neutral fat in HuH-7 cells due to the addition of various EPS
Polysaccharide Final concentration Accumulation amount of neutral fat (A600 nm) sample of polysaccharide 1st 2nd Average SE
(ng/mL) NC - 0.107 0.098 0.102 0.004 Vehicle - 0.104 0.095 0.100 0.004 PA/OA - 0.347 0.360 0.353 0.007 SONE68 4 0.198 0.279 0.239 0.041 5N35N 4 0.201 0.313 0.257 0.056 SONE68 40 0.098 0.222 0.160 0.062 Date recta/Date received 2020-06-16 SN35N 40 0.188 0.272 0.230 0.042 SONE68 400 0.085 0.103 0.094 0.009 SN35N 400 0.122 0.133 0.128 0.006
[Table 3]
Accumulation amount of neutral fat in HuH-7 cells due to the addition of various EPS
Polysaccharide Final concentration Accumulation amount of neutral fat (A600 nm) sample of polysaccharide 1st 2nd Average SE
(ng/mL) NC - 0.107 0.098 0.102 0.004 Vehicle - 0.104 0.095 0.100 0.004 PA/OA - 0.347 0.360 0.353 0.007 SONE68 4 0.198 0.279 0.239 0.041 5N35N 4 0.201 0.313 0.257 0.056 SONE68 40 0.098 0.222 0.160 0.062 Date recta/Date received 2020-06-16 SN35N 40 0.188 0.272 0.230 0.042 SONE68 400 0.085 0.103 0.094 0.009 SN35N 400 0.122 0.133 0.128 0.006
[0055]
In addition, Fig. 5 also shows the obtained results. As can be seen from the results in Table 3 and Fig. 5, the addition of only the PA/OA solution clearly increased the triglyceride (neutral fat) content in the cells. In addition, when only DMSO
(vehicle) as a solvent, in which the PA/OA was dissolved, was added, no change was observed like the case where nothing was added (NC). On the other hand, when a polysaccharide sample (EPS) (SONE68) produced by the strain IJH-SONE68 was added in the presence of the PA/0A, it was observed that the intake of fatty acids into cells was suppressed in a concentration-dependent manner and that fat accumulation was suppressed. The degree of the suppression was higher in the polysaccharide sample produced by the strain IJH-SONE68 than in the polysaccharide sample (EPS) (SN35N) produced by the strain SN35N.
From the above results, it was revealed that the polysaccharide produced by the strain IJH-SONE68 has an action of suppressing fat accumulation.
In addition, Fig. 5 also shows the obtained results. As can be seen from the results in Table 3 and Fig. 5, the addition of only the PA/OA solution clearly increased the triglyceride (neutral fat) content in the cells. In addition, when only DMSO
(vehicle) as a solvent, in which the PA/OA was dissolved, was added, no change was observed like the case where nothing was added (NC). On the other hand, when a polysaccharide sample (EPS) (SONE68) produced by the strain IJH-SONE68 was added in the presence of the PA/0A, it was observed that the intake of fatty acids into cells was suppressed in a concentration-dependent manner and that fat accumulation was suppressed. The degree of the suppression was higher in the polysaccharide sample produced by the strain IJH-SONE68 than in the polysaccharide sample (EPS) (SN35N) produced by the strain SN35N.
From the above results, it was revealed that the polysaccharide produced by the strain IJH-SONE68 has an action of suppressing fat accumulation.
[0056]
Example 4 Anti-obesity action and fat accumulation-suppressing action of the strain JIH-The anti-obesity action and fat accumulation-suppressing action of the strain IJH-SONE68 were evaluated using obese model mice ingesting high fat diets. As a result, it was revealed that the ingestion of a fermented pineapple juice fermented with the strain IJH-SONE68 significantly suppressed body weight gain and visceral fat accumulation in obese model mice ingesting high fat diets.
Example 4 Anti-obesity action and fat accumulation-suppressing action of the strain JIH-The anti-obesity action and fat accumulation-suppressing action of the strain IJH-SONE68 were evaluated using obese model mice ingesting high fat diets. As a result, it was revealed that the ingestion of a fermented pineapple juice fermented with the strain IJH-SONE68 significantly suppressed body weight gain and visceral fat accumulation in obese model mice ingesting high fat diets.
[0057]
1. Test method In the present test, C57BL/6Jcl (SPF) male mice were used. Seven-week-old mice were brought in a breeding cage, and five mice were kept per the breeding cage.
After one week of acclimatization using normal diets (MF, manufactured by Oriental Yeast Co., Ltd.), the mice were divided into groups of 5 mice (Groups A to E), and the diets were changed to high fat diets (Research Diet, # D12492), and the induction of obesity was started. When feeding the diets, the high-fat diets were ground in advance with a mallet to make them clay-like and packed in a powder feeder made of glass (KN-675-4A) so that 120 g was set per the feeding. The changes were made at weekly intervals. In addition, the administration sample was mixed with the high-fat diets so Date recu/Date received 2020-06-16 as to be uniform before packing in the feeder. All groups had free access to the diets and drinking water. The undiluted solution of a pineapple juice fermented with the strain IJH-SONE68, which was obtained by sterilizing a fermented broth obtained by culturing the strain IJH-SONE68 in 100% pineapple juice (containing 1 w/v%
distillation residue of distilled spirit) for 48 hours, at 121 C for 20 minutes, and its diluted solution were used as administration samples. The details of the administration samples for Groups A to F of the mice were as follows.
1. Test method In the present test, C57BL/6Jcl (SPF) male mice were used. Seven-week-old mice were brought in a breeding cage, and five mice were kept per the breeding cage.
After one week of acclimatization using normal diets (MF, manufactured by Oriental Yeast Co., Ltd.), the mice were divided into groups of 5 mice (Groups A to E), and the diets were changed to high fat diets (Research Diet, # D12492), and the induction of obesity was started. When feeding the diets, the high-fat diets were ground in advance with a mallet to make them clay-like and packed in a powder feeder made of glass (KN-675-4A) so that 120 g was set per the feeding. The changes were made at weekly intervals. In addition, the administration sample was mixed with the high-fat diets so Date recu/Date received 2020-06-16 as to be uniform before packing in the feeder. All groups had free access to the diets and drinking water. The undiluted solution of a pineapple juice fermented with the strain IJH-SONE68, which was obtained by sterilizing a fermented broth obtained by culturing the strain IJH-SONE68 in 100% pineapple juice (containing 1 w/v%
distillation residue of distilled spirit) for 48 hours, at 121 C for 20 minutes, and its diluted solution were used as administration samples. The details of the administration samples for Groups A to F of the mice were as follows.
[0058]
Group A: a group in which the mice ingested an undiluted solution of a pineapple juice fermented with the strain IJH-SONE68, together with high-fat diets (a group in which the mice ingested the mixture of 7 mL of an undiluted solution of the fermented pineapple juice and 120 g of high-fat diets).
Group B: a group in which the mice ingested a 10-fold diluted solution of a pineapple juice fermented with the strain IJH-SONE68, together with high-fat diets (a group in which the mice ingested the mixture of 7 mL of a 10-fold diluted fermented pineapple juice diluted with sterile distilled water and 120 g of high-fat diets).
Group C: a group in which the mice ingested a 100-fold diluted solution of a pineapple juice fermented with the strain IJH-SONE68, together with high-fat diets (a group in which the mice ingested the mixture of 7 mL of a 100-foled diluted solution of the fermented pineapple juice diluted with sterile distilled water and 120 g of high-fat diets).
Group D: a group in which the mice ingested an unfermented pineapple juice together with high-fat diets (a group in which the mice ingested the mixture of 7 mL of the pineapple juice and 120 g of high-fat diets).
Group E: a group in which the mice were bred only with high-fat diets (a positive control group) (a group in which the mice ingested the mixture of 7 mL of sterile distilled water and 120 g of high-fat diets).
Group F: a group in which the mice were bred only with an ordinary feed (a negative control group).
Group A: a group in which the mice ingested an undiluted solution of a pineapple juice fermented with the strain IJH-SONE68, together with high-fat diets (a group in which the mice ingested the mixture of 7 mL of an undiluted solution of the fermented pineapple juice and 120 g of high-fat diets).
Group B: a group in which the mice ingested a 10-fold diluted solution of a pineapple juice fermented with the strain IJH-SONE68, together with high-fat diets (a group in which the mice ingested the mixture of 7 mL of a 10-fold diluted fermented pineapple juice diluted with sterile distilled water and 120 g of high-fat diets).
Group C: a group in which the mice ingested a 100-fold diluted solution of a pineapple juice fermented with the strain IJH-SONE68, together with high-fat diets (a group in which the mice ingested the mixture of 7 mL of a 100-foled diluted solution of the fermented pineapple juice diluted with sterile distilled water and 120 g of high-fat diets).
Group D: a group in which the mice ingested an unfermented pineapple juice together with high-fat diets (a group in which the mice ingested the mixture of 7 mL of the pineapple juice and 120 g of high-fat diets).
Group E: a group in which the mice were bred only with high-fat diets (a positive control group) (a group in which the mice ingested the mixture of 7 mL of sterile distilled water and 120 g of high-fat diets).
Group F: a group in which the mice were bred only with an ordinary feed (a negative control group).
[0059]
After the content of the diets was changed from the high-fat diets to each of the above-mentioned diets of Groups A to F, the breeding was continued for 12 weeks.
The body weight of the mice was measured every week during the breeding period.
After the end of the breeding period, the mice were euthanized by isoflurane inhalation anesthesia, visceral fat was collected, and its weight was measured. An independent t-test was used for a significant difference test in each measurement data, and when a Date recu/Date received 2020-06-16 risk rate (p value) was less than 0.05, it was determined that there was a significant difference.
After the content of the diets was changed from the high-fat diets to each of the above-mentioned diets of Groups A to F, the breeding was continued for 12 weeks.
The body weight of the mice was measured every week during the breeding period.
After the end of the breeding period, the mice were euthanized by isoflurane inhalation anesthesia, visceral fat was collected, and its weight was measured. An independent t-test was used for a significant difference test in each measurement data, and when a Date recu/Date received 2020-06-16 risk rate (p value) was less than 0.05, it was determined that there was a significant difference.
[0060]
2. Test results and discussion Tables 4 and 5 show changes in the amount of body weight gain every one week (the amount increased from body weight at the start of breeding (week 0)) in each of Groups A to F (Table 4 shows the average body weight gain amount (g), and Table 5 shows the standard errors (SE)), and graphs thereof are shown in Fig. 6. In addition, Table 6 shows the average body weight gain amount of each Group at the last week of breeding (week 12), and graphs thereof are shown in Fig. 7. Each of the data is shown as a mean standard error, and Tukey-Kramer method was used for a significant difference test among the Groups, and it was determined that there was a significant difference when a risk factor (p value) was less than 0.05 (Figs. 6 and 7 disclosed herein below show only a significant difference from the positive control group).
2. Test results and discussion Tables 4 and 5 show changes in the amount of body weight gain every one week (the amount increased from body weight at the start of breeding (week 0)) in each of Groups A to F (Table 4 shows the average body weight gain amount (g), and Table 5 shows the standard errors (SE)), and graphs thereof are shown in Fig. 6. In addition, Table 6 shows the average body weight gain amount of each Group at the last week of breeding (week 12), and graphs thereof are shown in Fig. 7. Each of the data is shown as a mean standard error, and Tukey-Kramer method was used for a significant difference test among the Groups, and it was determined that there was a significant difference when a risk factor (p value) was less than 0.05 (Figs. 6 and 7 disclosed herein below show only a significant difference from the positive control group).
[0061]
[Table 4]
Average value (g) of body weight gain amount every elapsed week in each feed administration group (n = 5 for each group) Elapsed Group A Group B Group C Group D Group E Group F
weeks 1 4.26 5.12 3.88 4.60 4.82 3.27 2 5.82 3.48 4.66 5.64 6.02 3.73 3 5.84 6.32 6.04 7.50 7.32 5.00 4 6.98 5.24 6.88 9.62 9.38 5.40 7.94 5.52 8.38 11.62 10.22 5.90 6 9.06 5.52 9.44 12.78 11.64 6.63 7 6.38 5.78 9.98 15.46 13.10 6.90 8 8.78 8.02 10.52 16.88 14.38 7.07 9 10.58 8.26 12.58 19.32 15.92 8.60 12.32 9.16 14.06 20.92 17.18 8.80 11 11.52 10.54 15.98 22.98 18.28 9.33 12 12.34 11.68 16.94 24.62 19.98 9.50
[Table 4]
Average value (g) of body weight gain amount every elapsed week in each feed administration group (n = 5 for each group) Elapsed Group A Group B Group C Group D Group E Group F
weeks 1 4.26 5.12 3.88 4.60 4.82 3.27 2 5.82 3.48 4.66 5.64 6.02 3.73 3 5.84 6.32 6.04 7.50 7.32 5.00 4 6.98 5.24 6.88 9.62 9.38 5.40 7.94 5.52 8.38 11.62 10.22 5.90 6 9.06 5.52 9.44 12.78 11.64 6.63 7 6.38 5.78 9.98 15.46 13.10 6.90 8 8.78 8.02 10.52 16.88 14.38 7.07 9 10.58 8.26 12.58 19.32 15.92 8.60 12.32 9.16 14.06 20.92 17.18 8.80 11 11.52 10.54 15.98 22.98 18.28 9.33 12 12.34 11.68 16.94 24.62 19.98 9.50
[0062]
[Table 5]
Standard error (SE) of average value (g) of body weight gain amount Date recu/Date received 2020-06-16 every elapsed week in each feed administration group (n = 5 for each group) Elapsed Group A Group B Group C Group D Group E Group F
weeks 1 0.69 1.06 0.23 1.61 1.20 1.16 2 0.59 0.84 0.37 1.77 1.21 1.42 3 1.11 1.03 0.40 1.97 1.15 1.57 4 1.15 0.69 0.62 2.23 1.16 1.80 1.49 1.07 0.82 2.36 1.11 1.67 6 1.60 0.73 0.97 2.69 1.26 1.20 7 1.08 0.80 1.16 2.79 1.28 1.27 8 1.58 1.03 1.22 2.92 1.41 1.52 9 1.88 0.99 1.49 3.12 1.61 1.15 2.19 1.09 1.64 3.26 1.84 1.07 11 2.38 1.27 1.71 3.53 1.88 0.90 12 2.55 1.23 1.85 3.50 1.99 0.67
[Table 5]
Standard error (SE) of average value (g) of body weight gain amount Date recu/Date received 2020-06-16 every elapsed week in each feed administration group (n = 5 for each group) Elapsed Group A Group B Group C Group D Group E Group F
weeks 1 0.69 1.06 0.23 1.61 1.20 1.16 2 0.59 0.84 0.37 1.77 1.21 1.42 3 1.11 1.03 0.40 1.97 1.15 1.57 4 1.15 0.69 0.62 2.23 1.16 1.80 1.49 1.07 0.82 2.36 1.11 1.67 6 1.60 0.73 0.97 2.69 1.26 1.20 7 1.08 0.80 1.16 2.79 1.28 1.27 8 1.58 1.03 1.22 2.92 1.41 1.52 9 1.88 0.99 1.49 3.12 1.61 1.15 2.19 1.09 1.64 3.26 1.84 1.07 11 2.38 1.27 1.71 3.53 1.88 0.90 12 2.55 1.23 1.85 3.50 1.99 0.67
[0063]
[Table 6]
Average value (g) and standard error (SE) of body weight gain amount after 12 weeks in each feed administration group (n = 5 for each group) Week 12 Group A Group B Group C Group D Group E Group F
Average 12.34 11.68 16.94 24.62 19.98 9.50 value SE 2.55 1.23 1.85 3.50 1.99 0.67
[Table 6]
Average value (g) and standard error (SE) of body weight gain amount after 12 weeks in each feed administration group (n = 5 for each group) Week 12 Group A Group B Group C Group D Group E Group F
Average 12.34 11.68 16.94 24.62 19.98 9.50 value SE 2.55 1.23 1.85 3.50 1.99 0.67
[0064]
As can be seen from Tables 4 to 6 and Figs. 6 to 7, it was confirmed that the body weight of the positive control group (Group E) was significantly increased by the ingestion of the high-fat diets (p < 0.01), as compared to the negative control group (Group F). It was revealed that among the groups in which the mice ingested the fermented pineapple juice, the group in which the mice ingested the undiluted solution or the 10-fold diluted solution (Group A or B) showed a significant suppression on an increase in body weight due to the ingestion of high-fat diets (p < 0.05 for Groups A and B), as compared to the positive control group. In addition, when the mice ingested the 100-fold diluted solution of the fermented pineapple juice (Group C), the effect was attenuated, but an increase in the body weight was less than that in the positive control group. On the other hand, in the group in which the mice ingested the unfermented Date recu/Date received 2020-06-16 pineapple juice (Group D), an increase in the body weight was observed as compared to the positive control group, but no significant difference was observed.
As can be seen from Tables 4 to 6 and Figs. 6 to 7, it was confirmed that the body weight of the positive control group (Group E) was significantly increased by the ingestion of the high-fat diets (p < 0.01), as compared to the negative control group (Group F). It was revealed that among the groups in which the mice ingested the fermented pineapple juice, the group in which the mice ingested the undiluted solution or the 10-fold diluted solution (Group A or B) showed a significant suppression on an increase in body weight due to the ingestion of high-fat diets (p < 0.05 for Groups A and B), as compared to the positive control group. In addition, when the mice ingested the 100-fold diluted solution of the fermented pineapple juice (Group C), the effect was attenuated, but an increase in the body weight was less than that in the positive control group. On the other hand, in the group in which the mice ingested the unfermented Date recu/Date received 2020-06-16 pineapple juice (Group D), an increase in the body weight was observed as compared to the positive control group, but no significant difference was observed.
[0065]
Next, the measurement results of the amount of visceral fat in the mice of each group at the last week of breeding (week 12) are shown in Table 7 and Fig. 8
Next, the measurement results of the amount of visceral fat in the mice of each group at the last week of breeding (week 12) are shown in Table 7 and Fig. 8
[0066]
[Table 7]
Average value (mg) and standard error (SE) of the weight amount of visceral fat in the mice of each group at week 12 of breeding Group A Group B Group C Group D Group E Group F
Average 2735 1633 4108 6240 5172 1346 value
[Table 7]
Average value (mg) and standard error (SE) of the weight amount of visceral fat in the mice of each group at week 12 of breeding Group A Group B Group C Group D Group E Group F
Average 2735 1633 4108 6240 5172 1346 value
[0067]
As can be seen from Table 7 and Fig. 8, it was confirmed that the visceral fat amount was significantly increased due to the ingestion of the high-fat diets in the positive control group (p < 0.01), as compared to the negative control group.
Among the groups in which the mice ingested the fermented pineapple juice, the group in which the mice ingested the 10-fold diluted solution (Group B) showed a significant suppression on an increase in the visceral fat amount (p < 0.01) as compared to the positive control group; however, the ingestion of the undiluted solution (Group A) remained in a suppressive trend (p <0.1). On the other hand, when the mice ingested the 100-fold diluted solution of the fermented pineapple juice (Group C), the effect was attenuated. Furthermore, in the group in which the mice ingested the unfermented pineapple juice (Group D), an increase in the visceral fat amount was observed similarly to the body weight, as compared to the positive control group, but no significant difference was observed.
As can be seen from Table 7 and Fig. 8, it was confirmed that the visceral fat amount was significantly increased due to the ingestion of the high-fat diets in the positive control group (p < 0.01), as compared to the negative control group.
Among the groups in which the mice ingested the fermented pineapple juice, the group in which the mice ingested the 10-fold diluted solution (Group B) showed a significant suppression on an increase in the visceral fat amount (p < 0.01) as compared to the positive control group; however, the ingestion of the undiluted solution (Group A) remained in a suppressive trend (p <0.1). On the other hand, when the mice ingested the 100-fold diluted solution of the fermented pineapple juice (Group C), the effect was attenuated. Furthermore, in the group in which the mice ingested the unfermented pineapple juice (Group D), an increase in the visceral fat amount was observed similarly to the body weight, as compared to the positive control group, but no significant difference was observed.
[0068]
From the above results, it was revealed that the ingestion of the 10-fold diluted solution of the pineapple juice fermented with the strain IJH-SONE68 significantly suppressed both an increase in the body weight and an increase in the visceral fat, induced by the ingestion of high-fat diets. In the case of the ingestion of the undiluted solution and 100-fold diluted solution of the pineapple juice fermented with the strain UH-50NE68, it was confirmed that the effect was attenuated. This is considered to be due to the fact that components involved in the functionality of the mice were diluted in the 100-fold diluted solution. When the mice ingested the unfermented pineapple juice, Date recu/Date received 2020-06-16 the body weight increased more than the positive control group. Therefore, in the case of the pineapple juice fermented with the strain IJH-SONE68, it was considered that there was a possibility that the increase in the body weight was due to sugars remaining in the pineapple juice.
From the above results, it was revealed that the ingestion of the 10-fold diluted solution of the pineapple juice fermented with the strain IJH-SONE68 significantly suppressed both an increase in the body weight and an increase in the visceral fat, induced by the ingestion of high-fat diets. In the case of the ingestion of the undiluted solution and 100-fold diluted solution of the pineapple juice fermented with the strain UH-50NE68, it was confirmed that the effect was attenuated. This is considered to be due to the fact that components involved in the functionality of the mice were diluted in the 100-fold diluted solution. When the mice ingested the unfermented pineapple juice, Date recu/Date received 2020-06-16 the body weight increased more than the positive control group. Therefore, in the case of the pineapple juice fermented with the strain IJH-SONE68, it was considered that there was a possibility that the increase in the body weight was due to sugars remaining in the pineapple juice.
[0069]
As is clear from the foregoing detailed disclosures, the present invention provides the following inventions:
[1] A composition for suppressing fat accumulation, comprising, as an active ingredient, a cell body of a lactic acid bacterium belonging to Lactobacillus paracasei, a cultured product or fermented product thereof, or a polysaccharide produced thereby.
[2] The composition according to the above [1], wherein the composition is for preventing or improving obesity.
[3] The composition according to the above [1], wherein the composition is for preventing or improving fatty liver or liver dysfunction.
[4] The composition according to any one of the above [1] to [3], wherein the lactic acid bacterium is a lactic acid bacterium derived from a fig.
[5] The composition according to any one of the above [1] to [4], wherein the lactic acid bacterium is Lactobacillus paracasei strain UH-SONE68 (Accession No. NITE
BP-02242) or a lactic acid bacterium equivalent thereto.
[6] The composition according to any one of the above [1] to [5], wherein the cultured product or fermented product of the lactic acid bacterium is a cultured product or fermented product that is obtained by cultivating or fermenting the lactic acid bacteria in the presence of a fruit juice of pineapple genus plant.
[7] The composition according to any one of the above [1] to [5], wherein the polysaccharide is a neutral polysaccharide having a structure in which N-acetylglucosamines are linked with each other via a-1,6 bond.
[8] The composition according to any one of the above [1] to [5], wherein the polysaccharide is an acidic polysaccharide composed mainly of glucoses and mannoses.
[9] The composition according to any one of the above [1] to [8], wherein the composition is a food or drink composition.
[10] The composition according to the above [9], wherein the food or drink is a beverage, a functional food, a fermented food, or a supplement.
[11] The composition according to any one of the above [1] to [8], wherein the composition is a pharmaceutical composition.
[12] The composition according to any one of the above [1] to [8], wherein the composition is a feed composition.
Date recu/Date received 2020-06-16 [13] Use of a cell body of a lactic acid bacterium belonging to Lactobacillus paracasei, a cultured product or fermented product thereof, or a polysaccharide produced thereby, as an active ingredient of a composition for suppressing fat accumulation.
[14] The use according to the above [13], wherein the composition is for preventing or improving obesity.
[15] The use according to the above [13], wherein the composition is for preventing or improving fatty liver or liver dysfunction.
[16] The use according to any one of the above [13] to [15], wherein the lactic acid bacterium is a lactic acid bacterium derived from a fig.
[17] The use according to any one of the above [13] to [16], wherein the lactic acid bacterium is Lactobacillus paracasei strain UH-SONE68 (Accession No. NITE
BP-02242) or a lactic acid bacterium equivalent thereto.
[18] The use according to any one of the above [13] to [17], wherein the cultured product or fermented product of the lactic acid bacterium is a cultured product or fermented product that is obtained by cultivating or fermenting the lactic acid bacteria in the presence of a fruit juice of pineapple genus plant.
[19] The use according to any one of the above [13] to [17], wherein the polysaccharide is a neutral polysaccharide having a structure in which N-acetylglucosamines are linked with each other via a-1,6 bond.
[20] The use according to any one of the above [13] to [17], wherein the polysaccharide is an acidic polysaccharide composed mainly of glucoses and mannoses.
[21] The use according to any one of the above [13] to [20], wherein the composition is a food or drink composition.
[22] The use according to the above [21], wherein the food or drink is a beverage, a functional food, a fermented food, or a supplement.
[23] The use according to any one of the above [13] to [20], wherein the composition is a pharmaceutical composition.
[24] The use according to any one of the above [13] to [20], wherein the composition is a feed composition.
[25] A method for applying a composition comprising, as an active ingredient, a cell body of a lactic acid bacterium belonging to Lactobacillus paracasei, a cultured product or fermented product thereof, or a polysaccharide produced thereby, to a subject in need thereof, wherein the method suppresses fat accumulation in the subject.
[26] The method according to the above [25], wherein the method prevents or improves obesity.
[27] The method according to the above [25], wherein the method prevents or improves Date recu/Date received 2020-06-16 fatty liver or liver dysfunction.
[28] The method according to any one of the above [25] to [27], wherein the lactic acid bacterium is a lactic acid bacterium derived from a fig.
[29] The method according to any one of the above [25] to [28], wherein the lactic acid bacterium is Lactobacillus paracasei strain UH-SONE68 (Accession No. NITE
BP-02242) or a lactic acid bacterium equivalent thereto.
[30] The method according to any one of the above [25] to [29], wherein the cultured product or fermented product of the lactic acid bacterium is a cultured product or fermented product that is obtained by cultivating or fermenting the lactic acid bacteria in the presence of a fruit juice of pineapple genus plant.
[31] The method according to any one of the above [25] to [30], wherein the polysaccharide is a neutral polysaccharide having a structure in which N-acetylglucosamines are linked with each other via a-1,6 bond.
[32] The method according to any one of the above [25] to [30], wherein the polysaccharide is an acidic polysaccharide composed mainly of glucoses and mannoses.
[33] The method according to any one of the above [25] to [32], wherein the composition is a food or drink composition.
[34] The method according to the above [33], wherein the food or drink is a beverage, a functional food, a fermented food, or a supplement.
[35] The method according to any one of the above [25] to [32], wherein the composition is a pharmaceutical composition.
[36] The method according to any one of the above [25] to [32], wherein the composition is a feed composition.
Industrial Applicability
As is clear from the foregoing detailed disclosures, the present invention provides the following inventions:
[1] A composition for suppressing fat accumulation, comprising, as an active ingredient, a cell body of a lactic acid bacterium belonging to Lactobacillus paracasei, a cultured product or fermented product thereof, or a polysaccharide produced thereby.
[2] The composition according to the above [1], wherein the composition is for preventing or improving obesity.
[3] The composition according to the above [1], wherein the composition is for preventing or improving fatty liver or liver dysfunction.
[4] The composition according to any one of the above [1] to [3], wherein the lactic acid bacterium is a lactic acid bacterium derived from a fig.
[5] The composition according to any one of the above [1] to [4], wherein the lactic acid bacterium is Lactobacillus paracasei strain UH-SONE68 (Accession No. NITE
BP-02242) or a lactic acid bacterium equivalent thereto.
[6] The composition according to any one of the above [1] to [5], wherein the cultured product or fermented product of the lactic acid bacterium is a cultured product or fermented product that is obtained by cultivating or fermenting the lactic acid bacteria in the presence of a fruit juice of pineapple genus plant.
[7] The composition according to any one of the above [1] to [5], wherein the polysaccharide is a neutral polysaccharide having a structure in which N-acetylglucosamines are linked with each other via a-1,6 bond.
[8] The composition according to any one of the above [1] to [5], wherein the polysaccharide is an acidic polysaccharide composed mainly of glucoses and mannoses.
[9] The composition according to any one of the above [1] to [8], wherein the composition is a food or drink composition.
[10] The composition according to the above [9], wherein the food or drink is a beverage, a functional food, a fermented food, or a supplement.
[11] The composition according to any one of the above [1] to [8], wherein the composition is a pharmaceutical composition.
[12] The composition according to any one of the above [1] to [8], wherein the composition is a feed composition.
Date recu/Date received 2020-06-16 [13] Use of a cell body of a lactic acid bacterium belonging to Lactobacillus paracasei, a cultured product or fermented product thereof, or a polysaccharide produced thereby, as an active ingredient of a composition for suppressing fat accumulation.
[14] The use according to the above [13], wherein the composition is for preventing or improving obesity.
[15] The use according to the above [13], wherein the composition is for preventing or improving fatty liver or liver dysfunction.
[16] The use according to any one of the above [13] to [15], wherein the lactic acid bacterium is a lactic acid bacterium derived from a fig.
[17] The use according to any one of the above [13] to [16], wherein the lactic acid bacterium is Lactobacillus paracasei strain UH-SONE68 (Accession No. NITE
BP-02242) or a lactic acid bacterium equivalent thereto.
[18] The use according to any one of the above [13] to [17], wherein the cultured product or fermented product of the lactic acid bacterium is a cultured product or fermented product that is obtained by cultivating or fermenting the lactic acid bacteria in the presence of a fruit juice of pineapple genus plant.
[19] The use according to any one of the above [13] to [17], wherein the polysaccharide is a neutral polysaccharide having a structure in which N-acetylglucosamines are linked with each other via a-1,6 bond.
[20] The use according to any one of the above [13] to [17], wherein the polysaccharide is an acidic polysaccharide composed mainly of glucoses and mannoses.
[21] The use according to any one of the above [13] to [20], wherein the composition is a food or drink composition.
[22] The use according to the above [21], wherein the food or drink is a beverage, a functional food, a fermented food, or a supplement.
[23] The use according to any one of the above [13] to [20], wherein the composition is a pharmaceutical composition.
[24] The use according to any one of the above [13] to [20], wherein the composition is a feed composition.
[25] A method for applying a composition comprising, as an active ingredient, a cell body of a lactic acid bacterium belonging to Lactobacillus paracasei, a cultured product or fermented product thereof, or a polysaccharide produced thereby, to a subject in need thereof, wherein the method suppresses fat accumulation in the subject.
[26] The method according to the above [25], wherein the method prevents or improves obesity.
[27] The method according to the above [25], wherein the method prevents or improves Date recu/Date received 2020-06-16 fatty liver or liver dysfunction.
[28] The method according to any one of the above [25] to [27], wherein the lactic acid bacterium is a lactic acid bacterium derived from a fig.
[29] The method according to any one of the above [25] to [28], wherein the lactic acid bacterium is Lactobacillus paracasei strain UH-SONE68 (Accession No. NITE
BP-02242) or a lactic acid bacterium equivalent thereto.
[30] The method according to any one of the above [25] to [29], wherein the cultured product or fermented product of the lactic acid bacterium is a cultured product or fermented product that is obtained by cultivating or fermenting the lactic acid bacteria in the presence of a fruit juice of pineapple genus plant.
[31] The method according to any one of the above [25] to [30], wherein the polysaccharide is a neutral polysaccharide having a structure in which N-acetylglucosamines are linked with each other via a-1,6 bond.
[32] The method according to any one of the above [25] to [30], wherein the polysaccharide is an acidic polysaccharide composed mainly of glucoses and mannoses.
[33] The method according to any one of the above [25] to [32], wherein the composition is a food or drink composition.
[34] The method according to the above [33], wherein the food or drink is a beverage, a functional food, a fermented food, or a supplement.
[35] The method according to any one of the above [25] to [32], wherein the composition is a pharmaceutical composition.
[36] The method according to any one of the above [25] to [32], wherein the composition is a feed composition.
Industrial Applicability
[0070]
As disclosed in detail herein above, the composition of the present invention is effective in suppressing fat accumulation and can be used to prevent or improve obesity and also prevent or improve fatty liver or liver dysfunction. The composition of the present invention can be used as a food or drink, a medicine, and a feed. The composition of the present invention comprises, as an active ingredient, a cell body of a lactic acid bacterium belonging to Lactobacillus paracasei, a cultured product or fermented product thereof, or a polysaccharide produced thereby. Therefore, the composition of the present invention has high safety, can be applied for a long period of time, can be supplied in a large amount at low cost, and has extremely high utility and practicality.
Date recu/Date received 2020-06-16
As disclosed in detail herein above, the composition of the present invention is effective in suppressing fat accumulation and can be used to prevent or improve obesity and also prevent or improve fatty liver or liver dysfunction. The composition of the present invention can be used as a food or drink, a medicine, and a feed. The composition of the present invention comprises, as an active ingredient, a cell body of a lactic acid bacterium belonging to Lactobacillus paracasei, a cultured product or fermented product thereof, or a polysaccharide produced thereby. Therefore, the composition of the present invention has high safety, can be applied for a long period of time, can be supplied in a large amount at low cost, and has extremely high utility and practicality.
Date recu/Date received 2020-06-16
Claims (12)
- [Claim 1]
A composition for suppressing fat accumulation, comprising, as an active ingredient, a cell body of a lactic acid bacterium belonging to Lactobacillus paracasei, a cultured product or fermented product thereof, or a polysaccharide produced thereby. - [Claim 2]
The composition according to claim 1, wherein the composition is for preventing or improving obesity. - [Claim 3]
The composition according to claim 1, wherein the composition is for preventing or improving fatty liver or liver dysfunction. - [Claim 4]
The composition according to any one of claims 1 to 3, wherein the lactic acid bacterium is a lactic acid bacterium derived from a fig. - [Claim 5]
The composition according to any one of claims 1 to 4, wherein the lactic acid bacterium is Lactobacillus paracasei strain IJH-SONE68 (Accession No. NITE
BP-02242) or a lactic acid bacterium equivalent thereto. - [Claim 6]
The composition according to any one of claims 1 to 5, wherein the cultured product or fermented product of the lactic acid bacterium is a cultured product or fermented product that is obtained by cultivating or fermenting the lactic acid bacteria in the presence of a fruit juice of pineapple genus plant. - [Claim 7]
The composition according to claims 1 to 5, wherein the polysaccharide is a neutral polysaccharide having a structure in which N-acetylglucosamines are linked with each other via .alpha.-1,6 bond. - [Claim 8]
The composition according to any one of claims 1 to 6, wherein the polysaccharide is an acidic polysaccharide composed mainly of glucoses and mannoses. - [Claim 9]
The composition according to any one of claims 1 to 8, wherein the composition is a food or drink composition. - [Claim 10]
The composition according to claim 9, wherein the food or drink is a beverage, a functional food, a fermented food, or a supplement. - [Claim 11]
The composition according to any one of claims 1 to 8, wherein the composition is a pharmaceutical composition. - [Claim 12]
The composition according to any one of claims 1 to 8, wherein the composition is a feed composition.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018-084048 | 2018-04-25 | ||
JP2018084048 | 2018-04-25 | ||
PCT/JP2019/014997 WO2019208150A1 (en) | 2018-04-25 | 2019-04-04 | Composition for inhibiting fat accumulation |
Publications (2)
Publication Number | Publication Date |
---|---|
CA3086024A1 true CA3086024A1 (en) | 2019-10-31 |
CA3086024C CA3086024C (en) | 2022-02-08 |
Family
ID=68294100
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3086024A Active CA3086024C (en) | 2018-04-25 | 2019-04-04 | Composition for suppressing fat accumulation |
Country Status (9)
Country | Link |
---|---|
US (2) | US20210169952A1 (en) |
EP (1) | EP3760055A4 (en) |
JP (1) | JP6649539B1 (en) |
KR (1) | KR102368627B1 (en) |
CN (1) | CN111698913A (en) |
AU (1) | AU2019260952B2 (en) |
CA (1) | CA3086024C (en) |
TW (1) | TWI739078B (en) |
WO (1) | WO2019208150A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI746955B (en) * | 2018-04-25 | 2021-11-21 | 日商曾根農場股份有限公司 | Composition for Type I Allergy |
JP7195714B2 (en) * | 2020-10-19 | 2022-12-26 | 曽根ファーム株式会社 | Composition for inflammatory bowel disease |
TWI778556B (en) * | 2021-03-25 | 2022-09-21 | 生展生物科技股份有限公司 | A probiotic composition containing Lactobacillus paracasei S38 and Bacillus coagulans BC198 and its application in changing body composition |
CN113322216B (en) * | 2021-07-30 | 2021-11-05 | 北京量化健康科技有限公司 | Lactobacillus paracasei B111H and application thereof in metabolic syndrome |
TWI797769B (en) * | 2021-10-06 | 2023-04-01 | 樂牧生技股份有限公司 | Lactobacillus paracasei LM-141 isolate and application thereof |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03172171A (en) | 1989-11-30 | 1991-07-25 | Nippon Oil & Fats Co Ltd | Culture of microorganism |
JPH0515366A (en) | 1991-07-11 | 1993-01-26 | Morinaga Milk Ind Co Ltd | Proliferation promoter for lactic acid bacterium and bifidobacterium |
JP2835548B2 (en) | 1992-01-10 | 1998-12-14 | 森永乳業株式会社 | Production method of fermented milk |
EP1731137A1 (en) * | 2005-06-08 | 2006-12-13 | Nestec S.A. | Cosmetic or dermatologic composition against dry and/or sensitive skin |
EP1642570A1 (en) * | 2004-10-04 | 2006-04-05 | L'oreal | Cosmetic or dermatologic composition against dry and/or sensitive skin |
JP5247012B2 (en) | 2006-07-25 | 2013-07-24 | 雪印メグミルク株式会社 | Fatty liver suppressant |
JP2008214253A (en) | 2007-03-02 | 2008-09-18 | Snow Brand Milk Prod Co Ltd | Visceral fat reduction agent |
JP2009102270A (en) * | 2007-10-24 | 2009-05-14 | Tsujido Kagaku Kk | Fat metabolism inhibitor |
PT2123168E (en) * | 2008-05-16 | 2012-03-28 | Nestec Sa | Lactobacillus paracasei and weight control |
JP2010138147A (en) * | 2008-12-15 | 2010-06-24 | Op Bio Factory Co Ltd | Melanogenesis inhibitor, antioxidant, anti-inflammatory agent, external preparation for skin, and food and beverage |
JP2010252641A (en) * | 2009-04-22 | 2010-11-11 | Mitsubishi Rayon Co Ltd | Method for producing polysaccharide derived from lactic bacterium |
JP2011024453A (en) * | 2009-07-23 | 2011-02-10 | Mitsubishi Rayon Co Ltd | Method for producing polysaccharides |
TWI520685B (en) | 2009-10-15 | 2016-02-11 | Univ Hiroshima | Lactic acid bacteria proliferation promoter |
JP5659483B2 (en) * | 2009-12-01 | 2015-01-28 | 三菱化学フーズ株式会社 | Method for producing polysaccharides |
KR101873193B1 (en) * | 2010-06-08 | 2018-07-02 | 아사히 그룹 홀딩스 가부시키가이샤 | Agent for improving lipid metabolism |
WO2014171478A1 (en) * | 2013-04-17 | 2014-10-23 | サントリーホールディングス株式会社 | Composition containing bacterium belonging to genus lactobacillus |
SG11201607557WA (en) * | 2014-03-24 | 2016-10-28 | Otsuka Pharma Co Ltd | Novel lactobacillus paracasei strain |
BR112017002627A2 (en) * | 2014-08-18 | 2017-12-05 | Nestec Sa | Prebiotics to Reduce Future Obesity Risk |
PL3387156T3 (en) * | 2015-12-11 | 2020-11-16 | Precisionbiotics Group Limited | Lactobacillus casei for treating obesity and associated metabolic disorders |
JP6744542B2 (en) * | 2016-02-18 | 2020-08-19 | ヤヱガキ醗酵技研株式会社 | Method for culturing Lactobacillus Lactobacillus |
EP3483281A4 (en) * | 2017-06-09 | 2019-09-25 | Asahi Kohsan Corporation | Extracellular polysaccharide of lactic acid bacteria and use thereof |
CN110741073A (en) * | 2017-06-09 | 2020-01-31 | 曾根农场股份公司 | Novel lactic acid bacteria and use thereof |
-
2019
- 2019-03-28 TW TW108110967A patent/TWI739078B/en active
- 2019-04-04 EP EP19791742.0A patent/EP3760055A4/en not_active Withdrawn
- 2019-04-04 KR KR1020207014437A patent/KR102368627B1/en active IP Right Grant
- 2019-04-04 JP JP2019545811A patent/JP6649539B1/en active Active
- 2019-04-04 CA CA3086024A patent/CA3086024C/en active Active
- 2019-04-04 CN CN201980006267.2A patent/CN111698913A/en active Pending
- 2019-04-04 US US17/048,924 patent/US20210169952A1/en not_active Abandoned
- 2019-04-04 AU AU2019260952A patent/AU2019260952B2/en active Active
- 2019-04-04 WO PCT/JP2019/014997 patent/WO2019208150A1/en unknown
-
2022
- 2022-09-22 US US17/950,886 patent/US20230034847A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3760055A4 (en) | 2021-06-30 |
AU2019260952B2 (en) | 2020-11-12 |
TW202002801A (en) | 2020-01-16 |
CA3086024C (en) | 2022-02-08 |
JP6649539B1 (en) | 2020-02-19 |
US20230034847A1 (en) | 2023-02-02 |
JPWO2019208150A1 (en) | 2020-04-30 |
KR20200091403A (en) | 2020-07-30 |
TWI739078B (en) | 2021-09-11 |
KR102368627B1 (en) | 2022-02-28 |
WO2019208150A1 (en) | 2019-10-31 |
EP3760055A1 (en) | 2021-01-06 |
CN111698913A (en) | 2020-09-22 |
AU2019260952A1 (en) | 2020-05-07 |
US20210169952A1 (en) | 2021-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11447740B2 (en) | Lactic acid bacterium and use thereof | |
CA3086024C (en) | Composition for suppressing fat accumulation | |
CA3086031C (en) | Composition for contact dermatitis | |
CA3032579C (en) | Exopolysaccharide of lactic acid bacterium and use thereof | |
KR20130092182A (en) | Lactobacillus brevis with high alcohol dehydrogenase activity and dairy products, health functional food and food additives comprising the same | |
KR102543494B1 (en) | Novel probiotics and use thereof | |
US20200179466A1 (en) | Novel Bacterial Strain Of Lactobacillus And Immunostimulant Comprising The Same | |
CA3085995C (en) | Composition for type i allergy | |
KR20220057323A (en) | Composition for preventing, alleviating, or treating NAFLD, obesity, or dyslipidemia comprising Lactobacillus mudanjiangensis CKDB001 strain | |
US20230097535A1 (en) | Composition for inflammatory bowel disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20200626 |
|
EEER | Examination request |
Effective date: 20200626 |